<SEC-DOCUMENT>0001021771-24-000033.txt : 20240208
<SEC-HEADER>0001021771-24-000033.hdr.sgml : 20240208
<ACCEPTANCE-DATETIME>20240208160949
ACCESSION NUMBER:		0001021771-24-000033
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20240206
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240208
DATE AS OF CHANGE:		20240208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioRestorative Therapies, Inc.
		CENTRAL INDEX KEY:			0001505497
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				911835664
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37603
		FILM NUMBER:		24609150

	BUSINESS ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747
		BUSINESS PHONE:		(631) 760-8100

	MAIL ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stem Cell Assurance, Inc.
		DATE OF NAME CHANGE:	20101110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brt8k.htm
<DESCRIPTION>FORM 8-K DATED FEBRUARY 6, 2024
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:brtx="http://biorestorative.com/20240206" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Certilman Balin
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_78f3c570716a4a22b1ba1a04fbf8f808" contextRef="c20240206to20240206" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_64abddf646f24eae90547bf0ef75095e" contextRef="c20240206to20240206">0001505497</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="brtx-20240206.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20240206to20240206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><br/>
  </div>

  <div style="font-family: 'Times New Roman', Times, serif;">
    <div style="color: #000000;">
      <div>
        <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

      <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

      <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

      <div style="padding-bottom: 6pt;"> <br/>
      </div>

      <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_1f57f7206e734448aa8e50810b708215" contextRef="c20240206to20240206">8-K</ix:nonNumeric></div>

      <div style="text-align: center; font-weight: bold; font-size: 12pt;"> <br/>
      </div>

      <div style="text-align: center; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div style="text-align: center; font-size: 10pt;">PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>

      <div style="font-size: 10pt;"> <br/>
      </div>

      <div style="text-align: center; font-size: 10pt; font-weight: bold;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_a4f29460a15e45e5bf188614a1aca9d0" contextRef="c20240206to20240206" format="ixt:date-monthname-day-year-en">February 6, 2024</ix:nonNumeric></div>

      <div style="font-size: 12pt;"> <br/>
      </div>

      <div style="text-align: center; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_458235bfc8b642588ab640ef2cd241f8" contextRef="c20240206to20240206">BioRestorative Therapies, Inc.</ix:nonNumeric><br/>
      </div>

      <div style="font-size: 10pt; text-align: center;">(Exact name of registrant as specified in its charter) </div>

      <div style="font-size: 10pt; padding-bottom: 12pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">


  <tr>

    <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid #000000; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_b2cfda17f0f64ab584c03fdfde2ccc50" contextRef="c20240206to20240206" format="ixt-sec:stateprovnameen">Nevada</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 5%; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;">
              <div style="text-align: left; ">&#160;</div>
            </td>

    <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid #000000; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_b6afabd87de0467b9eb57b06f09b9eb8" contextRef="c20240206to20240206">001-37603</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 5%; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;">
              <div style="text-align: left; ">&#160;</div>
            </td>

    <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid #000000; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_a170d5152f2349ed95f7ef9b2c655bfc" contextRef="c20240206to20240206">30-1341024</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 30%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; ">(State or other jurisdiction <br/>
                of incorporation)</div>
            </td>

    <td style="width: 5%; vertical-align: bottom; font-size: 10pt;">
              <div style="text-align: left; ">&#160;</div>
            </td>

    <td style="width: 30%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; ">(Commission <br/>
                File Number)</div>
            </td>

    <td style="width: 5%; vertical-align: bottom; font-size: 10pt;">
              <div style="text-align: left; ">&#160;</div>
            </td>

    <td style="width: 30%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; ">(IRS Employer <br/>
                Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="font-size: 8pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">


  <tr>

    <td style="width: 47%; vertical-align: bottom; border-bottom: 2px solid #000000; text-align: center; font-size: 10pt; font-weight: bold;">
              <div><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_a8b8f1f2d3a84899a626646b12361390" contextRef="c20240206to20240206">40 Marcus Drive</ix:nonNumeric></div>
              <div><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_55c7ab22e710472c9ee246169f7c5e27" contextRef="c20240206to20240206">Melville</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_3fc4312b45b049f7b96091f26caa3f2e" contextRef="c20240206to20240206" format="ixt-sec:stateprovnameen">New York</ix:nonNumeric></div>
            </td>

    <td style="width: 6%; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;">
              <div style="text-align: left;">&#160;</div>
            </td>

    <td style="width: 47%; vertical-align: bottom; text-align: center; font-size: 10pt; border-bottom: 2px solid #000000; font-weight: bold">
              <div><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_55a1e10a132e48709d99f5b66662646c" contextRef="c20240206to20240206">11747</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 47%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; ">(Address of principal executive offices)</div>
            </td>

    <td style="width: 6%; vertical-align: bottom; font-size: 10pt;">
              <div style="text-align: left; ">&#160;</div>
            </td>

    <td style="width: 47.48%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; ">(Zip code)</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"> <br/>
      </div>

      <div style="text-align: center; font-size: 10pt;">Registrant's telephone number, including area code (<ix:nonNumeric name="dei:CityAreaCode" id="Fact_444fb7fa872f45508900b3c5a3e2629b" contextRef="c20240206to20240206">631</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_3d21d989d12a4fa5819e6384ecfc7e41" contextRef="c20240206to20240206">760-8100</ix:nonNumeric></div>

      <div style="font-size: 10pt;"> <br/>
      </div>

      <div style="text-align: center; font-size: 10pt;">Not Applicable</div>

      <div style="text-align: center; font-size: 10pt;">(Former Name or Former Address, if Changed Since Last Report)</div>

      <div style="font-size: 10pt;"> <br/>
      </div>

      <div style="text-align: center; font-size: 10pt;"><span style="text-decoration: underline;">Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:</span></div>

      <div style="text-align: center; font-size: 10pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">


  <tr>

    <td style="width: 33.33%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; "><span style="text-decoration: underline;">Title of each class</span></div>
            </td>

    <td style="width: 33.33%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; "><span style="text-decoration: underline;">Trading Symbol(s)</span></div>
            </td>

    <td style="width: 33.33%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; "><span style="text-decoration: underline;">Name of each exchange on which registered</span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 33.33%; vertical-align: bottom; font-size: 10pt; text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_f4f88e3acb8249a697e015f15babf183" contextRef="c20240206to20240206">BRTX</ix:nonNumeric><br/>
            </td>

    <td style="width: 33.33%; vertical-align: bottom; font-size: 10pt; text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_c7a42475c0cb4e90b411dd27e549447a" contextRef="c20240206to20240206">BRTX</ix:nonNumeric><br/>
            </td>

    <td style="width: 33.33%; vertical-align: bottom; font-size: 10pt; text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_ce0e7922fcdb4fffb7c34510457aef41" contextRef="c20240206to20240206">NASDAQ</ix:nonNumeric> Capital Market<br/>
            </td>

  </tr>


</table>
      <div style="margin-top: 6pt; margin-bottom: 6pt; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; margin-top: 6pt; margin-bottom: 6pt; font-size: 10pt;"> Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
        provisions (see General Instruction A.2. below): </div>

      <div style="text-align: left; margin-bottom: 7.1pt; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_ba3ebbc81a9b44499af20cca3f5090df" contextRef="c20240206to20240206" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities
        Act (17 CFR 230.425)</div>

      <div style="text-align: left; margin-bottom: 6.95pt; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_e77c6ff7804f4590aa4741e8de7df057" contextRef="c20240206to20240206" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act
        (17 CFR 240.14a-12)</div>

      <div style="text-align: left; margin-bottom: 6.95pt; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_85922a44fd364043b03c836711939c8f" contextRef="c20240206to20240206" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under
        the Exchange Act (17 CFR 240.14d-2(b))</div>

      <div style="text-align: left; margin-bottom: 2.05pt; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_a68e741c5a4243d3a55dc1e3aa3b1013" contextRef="c20240206to20240206" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under
        the Exchange Act (17 CFR 240.13e-4(c))</div>

      <div style="margin-bottom: 2.05pt; font-size: 10pt;"> <br/>
      </div>

      <div style="text-align: left; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act
        of 1934 (&#167;240.12b-2 of this chapter):</div>

      <div><br/>
      </div>

      <div style="text-align: left; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_777d37ca4b0b4e3aaada88abb46bd273" contextRef="c20240206to20240206" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

      <div><br/>
      </div>

      <div style="text-align: left; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
        provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

      <div style="margin-top: 6pt;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/> </div>

    </div>

  </div>

  <div> <br/>
  </div>

  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

  </div>

  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 14.36%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Item 1.01.</div>
          </td>

    <td style="width: 85.64%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Entry into a Material Definitive Agreement.</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">On February 6, 2024, BioRestorative Therapies, Inc. (the &#8220;Company&#8221;) entered into agreements (the &#8220;Agreements&#8221;) with <span style="font-family: 'Times New Roman',Times,serif;">certain holders of its existing warrants exercisable for an aggregate of 3,351,580 shares of its common stock (collectively, the &#8220;Existing Warrants&#8221;), to exercise their warrants at a reduced
        exercise price of $2.33 per share, in exchange for new warrants (the &#8220;New Warrants&#8221;) as described below.&#160; The aggregate gross proceeds from the exercise of the Existing Warrants and the payment of the New Warrants, as described below, is
        approximately $8.1 million, before deducting financial advisory fees. The reduction of the exercise price of the Existing Warrants and the issuance of the New Warrants was structured as an at-market transaction under Nasdaq rules.</span></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The Company intends to use the net proceeds from the warrant exercises in connection with its clinical trials with respect to its lead
      cell therapy candidate, <span style="font-family: 'Times New Roman',Times,serif; font-style: italic;">BRTX-100</span>, pre-clinical research and development with respect to its metabolic <span style="font-family: 'Times New Roman',Times,serif; font-style: italic;">ThermoStem Program</span> and for general corporate purposes and working capital.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The shares of common stock issuable upon exercise of the Existing Warrants are registered for issuance pursuant to a registration
      statement on Form S-1, as amended (File No. 333-258611), which was declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on November 4, 2021, or for resale pursuant to a registration statement on Form S-3 (File No. 333-265052),
      which was declared effective by the SEC on June 16, 2022.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">In consideration for the immediate exercise of the Existing Warrants for cash and the payment of $0.125 per share underlying the New
      Warrants, the exercising holders will receive the New Warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act").&#160; The New Warrants will be
      exercisable for a period of five years into an aggregate of up to 2,513,685 shares of common stock at an exercise price of $2.43 per share.&#160; The securities offered in the private placement have not been registered under the Securities Act or
      applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act
      and such applicable state securities laws. As part of the transaction, the Company has agreed to file a resale registration statement on Form S-3 with the SEC within ten days of the closing to register the resale of the shares of common stock
      underlying the New Warrants issued in the private placement.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">In connection with the transaction described above, the Company entered into a financial advisory services agreement, dated February 5,
      2024, with Roth Capital Partners, LLC (&#8220;Roth&#8221;), pursuant to which the Company has agreed to pay Roth a cash fee of approximately $528,000 for its services, in addition to reimbursement for certain expenses.</div>

    <div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The foregoing descriptions of the Agreements and the New Warrants are not complete and are qualified in their entirety by reference to the
      full texts of (i) the forms of the Agreements, copies of which are filed as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K and are incorporated by reference herein and (iii) the forms of the New Warrants, copies of which are filed as
      Exhibits 10.3 and 10.4 to this Current Report on Form 8-K and are incorporated by reference herein.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 16.94%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Item 3.02.</div>
          </td>

    <td style="width: 83.06%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Unregistered Sale of Equity Securities.</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Reference is made to Item 1.01 above.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 16.94%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Item 8.01</div>
          </td>

    <td style="width: 83.06%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Other Events.</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">On February 6, 2024, the Company issued a press release (the &#8220;Press Release&#8221;) regarding the transaction described in Item 1.01 above. A
      copy of the Press Release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 16.94%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Item 9.01.</div>
          </td>

    <td style="width: 83.06%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Financial Statements and Exhibits.</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(d)</span><span class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 45.8pt;">&#160;</span><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><span style="text-decoration: underline;">Exhibits</span></span></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 19.2%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Number</div>
          </td>

    <td style="width: 80.8%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Description</div>
          </td>

  </tr>

  <tr>

    <td style="width: 19.2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 80.8%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 19.2%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">10.1</div>
          </td>

    <td style="width: 80.8%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Form of Agreement, dated February 6, 2024, by and between the Company and the warrantholders (other than Auctus Fund, LLC).</div>
          </td>

  </tr>

  <tr>

    <td style="width: 19.2%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">10.2</div>
          </td>

    <td style="width: 80.8%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Form of Agreement, dated February 5, 2024, by and between the Company and Auctus Fund, LLC.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 19.2%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">10.3</div>
          </td>

    <td style="width: 80.8%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Form of New Warrant issued to warrantholders (other than Auctus Fund, LLC).</div>
          </td>

  </tr>

  <tr>

    <td style="width: 19.2%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">10.4</div>
          </td>

    <td style="width: 80.8%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Form of New Warrant issued to Auctus Fund, LLC.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 19.2%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">99.1</div>
          </td>

    <td style="width: 80.8%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Press release of the Company, dated February 6, 2024.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 19.2%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">104</div>
          </td>

    <td style="width: 80.8%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Cover Page Interactive Data File (embedded within the Inline&#160; XBRL document).</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
      by the undersigned hereunto duly authorized.</div>

  </div>

  <div><span style="font-size: 10pt;"> </span></div>

  <div>
<div><br/></div>

    <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; border-collapse: separate; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">


  <tr>

    <td valign="top" style="width: 50%;">&#160;</td>

    <td valign="top" style="width: 38%;" colspan="2"><strong>BIORESTORATIVE THERAPIES, INC.<br/>
            </strong></td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" style="width: 50%;">&#160;</td>

    <td valign="top" style="width: 3%;">&#160;</td>

    <td valign="top" style="width: 35%;">&#160;</td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" align="left" style="width: 50%; padding-bottom: 2px;">
            <div style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left;">Dated: February 7, 2024<br/>
            </div>
          </td>

    <td valign="top" style="width: 3%; padding-bottom: 2px;">
            <div style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left;">By: </div>
          </td>

    <td valign="top" align="left" style="width: 35%; border-bottom: #000000 2px solid; white-space: nowrap;">/s/ Lance Alstodt<br/>
          </td>

    <td valign="top" style="width: 12%; padding-bottom: 2px;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" style="width: 50%;">&#160;</td>

    <td valign="top" style="width: 3%;">&#160;</td>

    <td valign="bottom" align="left" style="width: 35%; white-space: nowrap;">Lance Alstodt<br/>
          </td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" style="width: 50%;">&#160;</td>

    <td valign="top" style="width: 3%;">&#160;</td>

    <td valign="top" style="width: 35%;">Chief Executive Officer<br/>
          </td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" style="width: 50%;">&#160;</td>

    <td valign="top" style="width: 3%;">&#160;</td>

    <td valign="top" style="width: 35%;">&#160;</td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>


</table>
    <div><br/></div>

  </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10_1.htm
<DESCRIPTION>AGREEMENT, BY AND BETWEEN THE COMPANY AND THE WARRANTHOLDERS (OTHER THAN AUCTUS FUND, LLC).
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Certilman Balin
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div><br>
  </div>
  <div style="text-align: right; text-indent: 36pt; margin-left: 288pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">February 6, 2024</div>
  <div><br>
  </div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">[Name and address of warrant holder]</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">Re:</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>Reprice and Reload Offer of Common Stock Purchase Warrants</u></font></div>
  <div><br>
  </div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">To Whom It May Concern:</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">BioRestorative Therapies, Inc. (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Company</u></font>&#8221;)
    is pleased to offer to you the opportunity to receive new Common Stock purchase warrants of the Company in consideration for the exercise of the Common Stock purchase warrants issued to you on or about November 9, 2021 (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Existing Warrants</u></font>&#8221;) and currently held by you (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Holder</u></font>&#8221;).&#160; The shares of common stock,
    par value $0.0001 (&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Common Stock</u></font>&#8221;), underlying the Existing Warrants (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Existing
        Warrant Shares</u></font>&#8221;) have been registered pursuant to a registration statement on <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">Form S-1, as amended (File No. 333-</font>258611<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">) (the &#8220;<u>Registration Statement</u></font>&#8221;).&#160; The Registration Statement is currently effective and, upon exercise
    of the Existing Warrants, will, to the Company&#8217;s knowledge, be effective for the issuance of the Existing Warrant Shares.<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Capitalized terms not otherwise
      defined herein shall have the meanings set forth in the Existing Warrants.</font></div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">The Company desires to reduce the Exercise Price of the Existing Warrants set forth on your signature page attached hereto to $<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">2.33</font> (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Reduced Exercise Price</u></font>&#8221;).&#160; In consideration for
    cash exercising of the Existing Warrants held by you and being exercised on the date hereof (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Warrant Exercise</u></font>&#8221;) on or before 8:00 a.m. (New York City time)
    on February 6, 2024 (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Offer Expiration Time</u></font>&#8221;) , the Company hereby offers to sell you or your designees a new Common Stock Purchase Warrant (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>New Warrants</u></font>&#8221;) to purchase up to a number of shares of Common Stock equal to 75% of the number of Existing Warrant Shares issued pursuant to each Warrant Exercise
    that occurs from and after the date hereof and prior to the Offer Expiration Time, which New Warrant (as defined below) shall be substantially in the form of the Existing Warrants.&#160; The purchase price of the New Warrant shall equal the $0.125 times the
    number of shares underlying the New Warrants.&#160; The new Common Stock Purchase Warrants will be immediately exercisable, expire five years from the Offer Expiration Time, and have an exercise price equal to <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">$2.43</font>, and will be in the form set forth on <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Annex B</u></font> hereto.&#160; The original New Warrant certificates
    will be delivered within two Business Days following the Offer Expiration Time.&#160; Notwithstanding anything herein to the contrary, in the event the Warrant Exercise would otherwise cause the Holder to exceed the beneficial ownership limitations (&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Beneficial Ownership Limitation</u></font>&#8221;) set forth in Section 2(e) of the Existing Warrants, the Company shall only issue such number of Warrant Shares to the Holder that
    would not cause the Holder to exceed the maximum number of Warrant Shares permitted thereunder with the balance to be held in abeyance until notice from the Holder that the balance (or portion thereof) may be issued in compliance with such limitations,
    which abeyance shall be evidenced through the Existing Warrant which shall be deemed prepaid thereafter, and exercised pursuant to a Notice of Exercise in the Existing Warrant (provided no additional exercise price shall be payable).</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">The Holder may accept this offer by signing this letter below, with such acceptance constituting the Holder&#8217;s exercise of the number of
    Existing Warrants as set forth on the Holder's signature page attached hereto for an aggregate exercise price as set forth on the Holder&#8217;s signature page hereto (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Aggregate
        Exercise Price</u></font>&#8221;) on or before the Offer Expiration Time.</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Additionally, the Company agrees to the representations, warranties and covenants set forth on <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Annex A</u></font> attached hereto. Holder represents and warrants that, as of the date hereof it is, and on each date on which it exercises any New Warrants it will be, an &#8220;accredited investor&#8221; as defined in Rule
    501 of the Securities Act, and agrees that the New Warrants will contain restrictive legends when issued, and neither the New Warrants nor the shares of Common Stock issuable upon exercise of the New Warrants will be registered under the Securities
    Act, except as provided in <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Annex A</u></font> attached hereto.&#160;</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">If this offer is accepted and this letter agreement is executed and delivered to the Company on or before the Offer Expiration Time, the
    Company shall issue a press release disclosing the material terms of the transactions contemplated hereby (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Press Release</u></font>&#8221;) on or before 9:00 a.m. (New York
    City time) on February 6, 2024 and (ii) file a Current Report on Form 8-K with the Securities and Exchange Commission disclosing all material terms of the transactions contemplated hereunder, including this letter agreement as an exhibit thereto with
    the Commission within the time required by the Exchange Act.&#160; From and after the issuance of the Press Release, the Company represents to the Holder that it shall have publicly disclosed all material, non-public information delivered to the Holder by
    the Company or any of its officers, directors, employees or agents in connection with the transactions contemplated hereby. In addition, effective upon the issuance of the Press Release, the Company acknowledges and agrees that any and all
    confidentiality or similar obligations under any agreement, whether written or oral, between the Company or any of its officers, directors, agents, employees or Affiliates on the one hand, and the Holder or any of its Affiliates on the other hand,
    shall terminate. From and after the issuance of the Press Release, the Company represents to the Holder that none of the Company&#8217;s directors, officers, employees or agents will provide the Holder with any material, nonpublic information that is not
    disclosed in the Press Release.</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">The Company acknowledges and agrees that the obligations of the Holder under this letter agreement are several and not joint with the
    obligations of any other holder of Common Stock purchase warrants of the Company issued pursuant to the Registration Statement or registered for resale pursuant to the registration statement on Form S-3, as amended ((File No. 333-365052) (each, an &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Other Holder</u></font>&#8221;) under any other agreement related to the exercise of such warrants (&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Other
        Warrant Exercise Agreement</u></font>&#8221;), and the Holder shall not be responsible in any way for the performance of the obligations of any Other Holder or under any such Other Warrant Exercise Agreement.&#160; Nothing contained in this letter agreement,
    and no action taken by the Holder pursuant hereto, shall be deemed to constitute the Holder and the Other Holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Holder and the Other
    Holders are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this letter agreement and the Company acknowledges that the Holder and the Other Holders are not acting in concert or as a group
    with respect to such obligations or the transactions contemplated by this letter agreement or any Other Warrant Exercise Agreement.&#160; The Company and the Holder confirm that the Holder has independently participated in the negotiation of the
    transactions contemplated hereby with the advice of its own counsel and advisors.&#160; The Holder shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this letter agreement, and it
    shall not be necessary for any Other Holder to be joined as an additional party in any proceeding for such purpose.</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">The Company hereby represents and warrants as of the date
      hereof and covenants and agrees from and after the date hereof until one year after the date hereof, that none of the terms offered to any Other Holder with respect to any Other Warrant Exercise Agreement (or any amendment, modification or waiver
      thereof), is or will be more favorable to such Other Holder than those of the Holder and this Agreement.&#160; If, and whenever on or after the date hereof</font>&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">until one year
      after the date hereof, the Company enters into an Other Warrant Exercise Agreement, then (i) the Company shall provide notice thereof to the Holder promptly following the occurrence thereof and (ii) the terms and conditions of this </font>letter
    agreement <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">shall be, without any further action by the Holder or the Company, automatically amended and modified in an economically and legally equivalent manner such that the
      Holder shall receive the benefit of the more favorable terms and/or conditions (as the case may be) set forth in such Other Warrant Exercise Agreement (including the issuance of additional Warrant Shares), provided that upon written notice to the
      Company at any time the Holder may elect not to accept the benefit of any such amended or modified term or condition, in which event the term or condition contained in this Agreement shall apply to the Holder as it was in effect immediately prior to
      such amendment or modification as if such amendment or modification never occurred with respect to the Holder.&#160; The provisions of this paragraph shall apply similarly and equally to each Other Warrant Exercise Agreement.</font></div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">The Company represents, warrants and covenants that, upon acceptance of this offer, all of the Existing Warrant Shares being exercised
    shall be delivered electronically through the Depository Trust Company within one (1) Trading Day of the date the Company receives the Aggregate Exercise Price (or, with respect to shares of Common Stock that would otherwise be in excess of the
    Beneficial Ownership Limitation, within one (1) Business Day of the date the Company is notified by Holder that its ownership is less than the Beneficial Ownership Limitation).&#160; Except as set forth herein, the terms of the Existing Warrants, including
    but not limited to the obligations to deliver the Existing Warrant Shares, shall remain in effect as if the acceptance of this offer was a formal exercise notice under the Existing Warrants.</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses
    incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this letter agreement. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery
    of any Existing Warrant Shares.&#160; This letter agreement shall be governed by the laws of the State of New York without regard to the principles of conflicts of law thereof.</div>
  <div><br>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">***************</div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">To accept this offer and to provide written consent to reduce the Exercise Price of the Existing Warrants, Holder must counter execute
    this letter agreement and return the fully executed letter agreement to the Company at e-mail: lalstodt@biorestorative.com, attention: Lance Alstodt, CEO, on or before the Offer Expiration Time.</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Please do not hesitate to call me if you have any questions.</div>
  <div><br>
  </div>
  <div style="text-align: justify; margin-left: 216pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Sincerely yours,</div>
  <div><br>
  </div>
  <div style="text-align: justify; margin-left: 216pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">BIORESTORATIVE THERAPIES, INC.</div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div style="text-align: justify; margin-left: 216pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">By: _______________________</div>
  <div style="text-align: justify; margin-left: 216pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Name: Lance Alstodt</div>
  <div style="text-align: justify; margin-left: 216pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Title: Chief Executive Officer</div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div><br>
  </div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Accepted and Agreed to:</div>
  <div><br>
  </div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Name of Holder: ________________________________________________________</div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Signature of Authorized Signatory of Holder</font>:
    _________________________________</div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Name of Authorized Signatory: _______________________________________________</div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Title of Authorized Signatory: ________________________________________________</div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Existing Warrants being exercised:____________</div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">July Warrants being exercised: ___________________</div>
  <div><br>
  </div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Aggregate Exercise Price of the Existing Warrants at the Reduced Exercise Price being exercised contemporaneously with signing this letter:
    $___________________ ($2.33 x Existing Warrants)</div>
  <div><br>
  </div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">New Warrant Shares: _________________</div>
  <div><br>
  </div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">New Warrant Purchase Price: $______________ ($0.125 x New Warrant Shares)</div>
  <div><br>
  </div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Beneficial Ownership Limitation New Warrant: 4.99%/9.99%</div>
  <div><br>
  </div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Address for Delivery of New Warrant: _________________________</div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">DTC Instructions:</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">The Existing Warrant Shares shall be delivered to the following DWAC Account Number:</div>
  <div><br>
  </div>
  <table cellspacing="0" cellpadding="0" id="z37dab105cc4c43c5b0ca95aac6f4c8f8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

      <tr>
        <td style="width: 27.21%; vertical-align: top;">
          <div>&#160;</div>
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Broker Name:</div>
        </td>
        <td style="width: 2.92%; vertical-align: top;">&#160;</td>
        <td style="width: 69.87%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
      </tr>
      <tr>
        <td style="width: 27.21%; vertical-align: top;">
          <div>&#160;</div>
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Broker DTC DWAC #:</div>
        </td>
        <td style="width: 2.92%; vertical-align: top;">&#160;</td>
        <td style="width: 69.87%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
      </tr>
      <tr>
        <td style="width: 27.21%; vertical-align: top;">
          <div>&#160;</div>
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Broker Contact:</div>
        </td>
        <td style="width: 2.92%; vertical-align: top;">&#160;</td>
        <td style="width: 69.87%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
      </tr>
      <tr>
        <td style="width: 27.21%; vertical-align: top;">
          <div>&#160;</div>
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Account #:</div>
        </td>
        <td style="width: 2.92%; vertical-align: top;">&#160;</td>
        <td style="width: 69.87%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
      </tr>

  </table>
  <div><br>
  </div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"><u>Annex A &#8211; Representations and Warranties</u></div>
  <div><br>
  </div>
  <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Representations, Warranties and Covenants of the Company</u></font>.&#160;
    The Company hereby makes the following representations and warranties to the Holder:</div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zdbe9959190a14dceaef34dbb051be29f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(a)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Registration Statements</u></font>.
              The Existing Warrant Shares have been registered pursuant to the Registration Statement and the Company knows of no reason why the Registration Statements shall not remain effective for the foreseeable future. The Company shall use
              commercially reasonable efforts to keep the Registration Statement effective and available for use by the Holder until all Existing Warrant Shares underlying the Existing Warrants are sold by the Holder.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zd383559ce8a6460e812349427e734f75" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(b)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Authorization; Enforcement</u></font>.&#160;
              The Company will have the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this letter agreement and otherwise to carry out its obligations hereunder and thereunder.&#160; The execution and
              delivery of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby will be duly authorized by all necessary action on the part of the Company and no further action is required by the
              Company, its board of directors or its stockholders in connection therewith.&#160; This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding
              obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
              application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and
              contribution provisions may be limited by applicable law.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zbe459b2c35f34b49aa04d3c500c1ddd3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(c)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>No Conflicts</u></font>.&#160;
              The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company&#8217;s
              certificate of incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of
              any Lien upon any of the properties or assets of the Company in connection with, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement,
              credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company is a party or by which any property or asset of the Company is bound or affected, other than for
              which a waiver has been obtained by the Company; or (iii) subject to Section (d) below, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental
              authority to which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zdb8c60d460fa432698ebb647c2dbfde1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(d)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Nasdaq Corporate Governance</u></font>.
              To the Company&#8217;s knowledge, the transactions contemplated under this letter agreement, comply with all rules of Nasdaq.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="za41fbbf142cc4f63a589103d1bd72b2f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(e)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Issuance of the New Warrant</u></font>.
              The issuance of the New Warrants will be duly authorized and, upon the execution of this letter agreement by the undersigned, will be duly and validly issued, fully paid and nonassessable, free and clear of all liens imposed by the Company,
              and the shares issuable upon exercise of the New Warrant (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>New Warrant Shares</u></font>&#8221;), when issued in accordance with the terms of the New Warrant, will
              be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company will reserve from its duly authorized capital stock a number of shares of Common Stock for issuance of the New Warrant Shares in
              full.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z84770fe760984584926df1f44a1352f0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(f)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>Legends and Transfer Restrictions.</u></div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zdb30e841d0484859aab3146b6da3b073" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 54pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(i)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;&#160;The New Warrant and New Warrant Shares may only be disposed of in compliance with state and federal securities laws. In
              connection with any transfer of New Warrant or New Warrant Shares other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of the undersigned or in connection with a pledge, the Company may
              require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to
              the effect that such transfer does not require registration of such transferred New Warrant and New Warrant Shares under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of
              this letter agreement.</div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z5c0290247a814cbaba980a9d12e7d05b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 54pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(ii)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;&#160;The undersigned agrees to the imprinting, so long as is required by this Section (i), of a legend on any of the New Warrant
              and New Warrant Shares in the following form:</div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div style="text-align: justify; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
    COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.&#160; THIS SECURITY
    AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES..</div>
  <div style="margin-bottom: 6pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 54pt;"><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 18pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">The Company acknowledges and agrees that the undersigned may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all of the New Warrant to a
      financial institution that is an &#8220;accredited investor&#8221; as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this letter agreement and, if required under the terms of such arrangement, the undersigned may
      transfer pledged or secured New Warrant to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in
      connection therewith. Further, no notice shall be required of such pledge. At the appropriate undersigned&#8217;s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of New Warrant may reasonably
      request in connection with a pledge or transfer of the New Warrant or New Warrant Shares.</font></div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z8d2d9ebb993d43b19587376d566b9c05" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 54pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(iii)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;Certificates evidencing the New Warrant Shares shall not contain any legend (including the legend set forth in Section (f)(ii)
              hereof), (i) while a registration statement covering the resale of such security is effective under the Securities Act, (ii) following any sale of such New Warrant Shares pursuant to Rule 144,&#160; or (iii) if such New Warrant Shares are eligible
              for sale under Rule 144. The Company shall cause its counsel to issue a legal opinion to its transfer agent (if required by the transfer agent) and the undersigned (if requested by the undersigned) in connection with the removal of the legend
              hereunder. If all or any portion of a New Warrant is exercised at a time when there is an effective registration statement to cover the resale of the New Warrant Shares, or if such New Warrant Shares may be sold under Rule 144, then such New
              Warrant Shares shall be issued free of all legends. The Company agrees that following such time as such legend is no longer required under this clause (iii), it will, no later than the earlier of (i) two (2) Trading Days and (ii) the number
              of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing Warrant Shares, as applicable, issued with a restrictive
              legend (such date, the &#8220;Legend Removal Date&#8221;), deliver or cause to be delivered to the undersigned a certificate representing such shares that is free from all restrictive and other legends. The Company may not make any notation on its
              records or give instructions to the transfer agent that enlarge the restrictions on transfer set forth in this Section (f). Certificates for New Warrant Shares subject to legend removal hereunder shall be transmitted by the transfer agent to
              the undersigned by crediting the account of the undersigned&#8217;s prime broker with the Depository Trust Company System as directed by the undersigned. &#8220;Standard Settlement Period&#8221; means the standard settlement period, expressed in a number of
              Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of a certificate representing Warrant Shares issued with a restrictive legend.</div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z863a6168ac3a440cb96388d2520c4ea9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 54pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(iv)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;&#160;In addition to such undersigned&#8217;s other available remedies, the Company shall pay to the undersigned, in cash, (i) as partial
              liquidated damages and not as a penalty, for each $1,000 of New Warrant Shares (based on the VWAP of the Common Stock on the date such Securities are submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject
              to Section (f)(iii), $10 per Trading Day (increasing to $20 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate is delivered without a legend
              and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to the undersigned by the Legend Removal Date a certificate representing the Securities so delivered to the Company by such undersigned that is free from all
              restrictive and other legends and (b) if after the Legend Removal Date such undersigned purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such undersigned of all or any
              portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock that such undersigned anticipated receiving from the Company without any
              restrictive legend, then, an amount equal to the excess of such undersigned&#8217;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including brokerage
              commissions and other out-of-pocket expenses, if any) (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Buy-In Price</u></font>&#8221;) over the product of (A) such number of New Warrant Shares that the Company
              was required to deliver to such undersigned by the Legend Removal Date multiplied by (B) the lowest closing sale price of the Common Stock on any Trading Day during the period commencing on the date of the delivery by such undersigned to the
              Company of the applicable New Warrant Shares (as the case may be) and ending on the date of such delivery and payment under this clause (ii).</div>
          </td>
        </tr>

    </table>
  </div>
  <div style="text-align: left; margin-left: 0.05pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"> </font><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z40db52e9ab3f47f7965a906272e60635" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(g)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Public Information Failure</u></font>. At any
              time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of the New Warrant Shares may be sold without the requirement for the Company to be in compliance with Rule 144(c)(1) and
              otherwise without restriction or limitation pursuant to Rule 144, if there is no effective registration statement covering the resale of all of the New Warrant Shares and the Company (i) shall fail for any reason to satisfy the current public
              information requirement under Rule 144(c) or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes an issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) (a &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Public Information Failure</u></font>&#8221;) then, in addition to the undersigned&#8217;s other available remedies, the Company shall pay to the undersigned, in cash, as partial
              liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the New Warrant Shares, an amount in cash equal to two percent (2.0%) of the aggregate Exercise Price of the undersigned&#8217;s New Warrant
              on the day of a Public Information Failure and on every thirtieth (30th) day (pro-rated for periods totaling less than thirty days) thereafter until the earlier of (a) the date such Public Information Failure is cured and (b) such time that
              such public information is no longer required&#160; for the undersigned to transfer the New Warrant Shares pursuant to Rule 144.&#160; The payments to which the undersigned shall be entitled pursuant to this Section (g) are referred to herein as
              &#8220;Public Information Failure Payments.&#8221; Public Information Failure Payments shall be paid on the earlier of (i) the last day of the calendar month during which such Public Information Failure Payments are incurred and (ii) the third (3rd)
              Business Day after the event or failure giving rise to the Public Information Failure Payments is cured.&#160; In the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information Failure Payments
              shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Nothing herein shall limit the undersigned&#8217;s right to pursue actual damages for the Public Information Failure, and the undersigned shall have
              the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief.</div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z25848ce00ce74fad8287749d3b8ef858" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(h)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Listing of Common Stock</u></font>. The Company
              shall apply to list or quote all of the New Warrant Shares on Nasdaq and promptly secure the listing of all of the New Warrant Shares on Nasdaq.</div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zc0e948e43b244a6b95e84a927a4c9059" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(i)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Registration Statement</u></font>.&#160; As soon as
              practicable (and in any event within ten (10) calendar days of the date of this Agreement), the Company shall file a registration statement on Form S-3 (or other appropriate form if the Company is not then S-3 eligible) providing for the
              resale by the Holders of the New Warrant Shares issued and issuable upon exercise of the New Warrants.&#160; The Company shall use commercially reasonable efforts to cause such registration to become effective on or prior to the 30<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>
              calendar day after the initial filing date and to keep such registration statement effective at all times until no Holder owns any New Warrants or New Warrant Shares issuable upon exercise thereof.</div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z407f8bdd0fdf42a0b86878d5a8df0737" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(j)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Subsequent Equity Sales</u></font>.&#160; From the
              date hereof until 45 days following the date hereof, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock
              Equivalents or (ii) file any registration statement or any amendment or supplement thereto, in each case other than the registration statement registering the New Warrant Shares or a registration statement on Form S-8.&#160; Notwithstanding the
              foregoing, this Section (j) shall not apply in respect of an Exempt Issuance.&#160; As used herein, &#8220;Exempt Issuance&#8221; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant to any
              stock or option plan duly adopted for such purpose by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) securities upon the
              exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that
              such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (except for such decreases in exercise,
              exchange or conversion price in accordance with the terms of such securities) or to extend the term of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested
              directors of the Company, provided that such securities are issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith
              until the registration statement registering all of the New Warrant Shares is declared effective, and provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its
              subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a
              transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zc2e3ca812cce45f29af59b21ea5a2c0e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(k)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">From the date hereof until the one-year anniversary of the date hereof, the Company shall be prohibited from effecting or
              entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction.&#160; &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Variable Rate Transaction</u></font>&#8221; means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for,
              or include the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies with, the trading prices of or quotations for the shares of
              Common Stock at any time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity
              security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including,
              but not limited to, an equity line of credit or an &#8220;at-the-market offering,&#8221; whereby the Company may issue securities at a future determined price, regardless of whether shares pursuant to such agreement have actually been issued and
              regardless of whether such agreement is subsequently canceled; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font>, <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>however</u></font>,
              that, after the six month anniversary of the Closing Date, the entry into and/or issuance of shares of Common Stock in an &#8220;at the market&#8221; offering shall not be deemed a Variable Rate Transaction.&#160; The Holder shall be entitled to obtain
              injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"><u>Annex B &#8211; Form of New Warrant</u></div>
  <div><br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex10_2.htm
<DESCRIPTION>AGREEMENT, BY AND BETWEEN THE COMPANY AND AUCTUS FUND, LLC
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Certilman Balin
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; text-indent: 36pt; margin-left: 288pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">February 5, 2024</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Auctus Fund, LLC</div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">545 Boylston Street, 2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup> Floor</div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Boston, MA 02116</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">Re:</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>Reprice and Reload Offer of Common Stock Purchase Warrants</u></font></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">To Whom It May Concern:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">BioRestorative Therapies, Inc. (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Company</u></font>&#8221;)
      is pleased to offer to you the opportunity to receive new Common Stock purchase warrants of the Company in consideration for the exercise of the Common Stock purchase warrants issued to you on or about November 9, 2021 (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Existing Warrants</u></font>&#8221;) and currently held by you (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Holder</u></font>&#8221;).&#160; The shares of common stock,
      par value $0.0001 (&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Common Stock</u></font>&#8221;), underlying the Existing Warrants (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Existing
          Warrant Shares</u></font>&#8221;) have been registered pursuant to a registration statement on <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">Form S-3, as amended (File No. 333-</font>265052<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">) (the &#8220;<u>Registration Statement</u></font>&#8221;).&#160; The Registration Statement is currently effective and, upon exercise
      of the Existing Warrants, will, to the Company&#8217;s knowledge, be effective for the issuance of the Existing Warrant Shares.<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Capitalized terms not otherwise
        defined herein shall have the meanings set forth in the Existing Warrants.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">The Company desires to reduce the Exercise Price of the Existing Warrants set forth on your signature page attached hereto to $<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">2.33</font> per share (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Reduced Exercise Price</u></font>&#8221;) and amend the
      Beneficial Ownership Limitation (as defined in the Existing Warrants) from 4.99% to 9.99% as provided for in the Existing Warrants as of the date hereof.&#160; In consideration for cash exercising of the Existing Warrants held by you and being exercised
      on the date hereof (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Warrant Exercise</u></font>&#8221;) on or before 8:00 a.m. (New York City time) on February 6, 2024 (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Offer Expiration Time</u></font>&#8221;) , the Company hereby offers to sell you or your designees a new Common Stock Purchase Warrant (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>New
          Warrants</u></font>&#8221;) to purchase up to a number of shares of Common Stock equal to 75% of the number of Existing Warrant Shares issued pursuant to each Warrant Exercise that occurs from and after the date hereof and prior to the Offer Expiration
      Time, which New Warrant (as defined below) shall be in the form set forth on <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Annex B</u></font> hereto.&#160; The purchase price of the New Warrant shall equal the $0.125
      times the number of shares underlying the New Warrants.&#160; The new Common Stock Purchase Warrants will be immediately exercisable, expire five years from the Offer Expiration Time, have an exercise price equal to <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">$2.43</font>, and will be in the form set forth on <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Annex B</u></font> hereto.&#160; The original New
      Warrant certificates will be delivered within two Business Days following the Offer Expiration Time.&#160; Notwithstanding anything herein to the contrary, in the event the Warrant Exercise would otherwise cause the Holder to exceed the Beneficial
      Ownership Limitation (as defined in the Existing Warrants) set forth in Section 2(e) of the Existing Warrants (as amended above), the Company shall only issue such number of Warrant Shares to the Holder that would not cause the Holder to exceed the
      maximum number of Warrant Shares permitted thereunder with the balance to be held in abeyance until notice from the Holder that the balance (or portion thereof) may be issued in compliance with such limitations, which abeyance shall be evidenced
      through the Existing Warrant which shall be deemed prepaid thereafter, and exercised pursuant to a Notice of Exercise in the Existing Warrant (provided no additional exercise price shall be payable).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">The Holder may accept this offer by signing this letter below, with such acceptance constituting the Holder&#8217;s exercise of the number of
      Existing Warrants as set forth on the Holder's signature page attached hereto for an aggregate exercise price as set forth on the Holder&#8217;s signature page hereto (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Aggregate
          Exercise Price</u></font>&#8221;) on or before the Offer Expiration Time.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Additionally, the Company agrees to the representations, warranties and covenants set forth on <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Annex A</u></font> attached hereto. Holder represents and warrants that, as of the date hereof it is, and on each date on which it exercises any New Warrants it will be, an &#8220;accredited investor&#8221; as
      defined in Rule 501 of the Securities Act, and agrees that the New Warrants will contain restrictive legends when issued, and neither the New Warrants nor the shares of Common Stock issuable upon exercise of the New Warrants will be registered under
      the Securities Act, except as provided in <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Annex A</u></font> attached hereto.&#160;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">If this offer is accepted and this letter agreement is executed and delivered to the Company on or before the Offer Expiration Time, the
      Company shall issue a press release disclosing the material terms of the transactions contemplated hereby (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Press Release</u></font>&#8221;) on or before 9:00 a.m. (New
      York City time) on February 6, 2024 and (ii) file a Current Report on Form 8-K with the Securities and Exchange Commission disclosing all material terms of the transactions contemplated hereunder, including this letter agreement as an exhibit thereto
      with the Commission within the time required by the Exchange Act.&#160; From and after the issuance of the Press Release, the Company represents to the Holder that it shall have publicly disclosed all material, non-public information delivered to the
      Holder by the Company or any of its officers, directors, employees or agents in connection with the transactions contemplated hereby. In addition, effective upon the issuance of the Press Release, the Company acknowledges and agrees that any and all
      confidentiality or similar obligations under any agreement, whether written or oral, between the Company or any of its officers, directors, agents, employees or affiliates on the one hand, and the Holder or any of its affiliates on the other hand,
      shall terminate. From and after the issuance of the Press Release, the Company represents to the Holder that none of the Company&#8217;s directors, officers, employees or agents will provide the Holder with any material, nonpublic information that is not
      disclosed in the Press Release.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">The Company represents, warrants and covenants that, upon acceptance of this offer, all of the Existing Warrant Shares being exercised
      shall be delivered electronically through the Depository Trust Company within one (1) Trading Day of the date the Company receives the Aggregate Exercise Price (the &#8220;Share Delivery Deadline&#8221;) (or, with respect to shares of Common Stock that would
      otherwise be in excess of the Beneficial Ownership Limitation and that are being held in abeyance as provided in this letter, within one (1) Business Day of the date the Company is notified by Holder that its ownership is less than the Beneficial
      Ownership Limitation).&#160; Except as set forth herein, the terms of the Existing Warrants, including but not limited to the obligations to deliver the Existing Warrant Shares, shall remain in effect as if the acceptance of this offer was a formal
      exercise notice under the Existing Warrants.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses
      incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this letter agreement. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the
      delivery of any Existing Warrant Shares.&#160; Notwithstanding anything in the Existing Warrants to the contrary, this letter agreement and the transactions contemplated hereby shall be governed by the laws of the State of Delaware without regard to the
      principles of conflicts of law thereof.&#160; Notwithstanding anything in the Existing Warrants to the contrary, each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this
      letter agreement (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">City of New York, Borough of Manhattan</font>. Each party hereby irrevocably submits to the exclusive jurisdiction of the <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">City of New York, Borough of Manhattan </font>for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees
      not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.&#160; Each party hereby
      irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at
      the address in effect for notices to it under this letter agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to
      serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this letter agreement, the prevailing party in such action, suit or proceeding shall be reimbursed by the
      other party for their reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">The Company acknowledges and agrees that the obligations of the Holder under this letter agreement are several and not joint with the
      obligations of any other holder or holders of warrants to purchase Common Stock of the Company that have been issued by the Company (each, an &#8220;Other Holder&#8221;) under any other agreement related to such warrants (&#8220;Other Warrant Agreement&#8221;), and the
      Holder shall not be responsible in any way for the performance of the obligations of any Other Holder or under any such Other Warrant Agreement.&#160; Nothing contained in this letter agreement, and no action taken by the Holder pursuant hereto, shall be
      deemed to constitute the Holder and the Other Holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Holder and the Other Holders are in any way acting in concert or as a group with
      respect to such obligations or the transactions contemplated by this letter agreement and the Company acknowledges that the Holder and the Other Holders are not acting in concert or as a group with respect to such obligations or the transactions
      contemplated by this letter agreement or any Other Warrant Agreement.&#160; The Company and the Holder confirm that the Holder has independently participated in the negotiation of the transactions contemplated hereby with the advice of its own counsel and
      advisors.&#160; The Holder shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Exchange Offer and Amendment, and it shall not be necessary for any Other Holder to be joined as an
      additional party in any proceeding for such purpose.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">This letter agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is
      not for the benefit of, nor may any provision hereof be enforced by, any other person.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">No provision of this letter agreement may be waived, modified, supplemented or amended. except in a written instrument signed by the
      Company and the Holder.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">This letter agreement may be executed in two or more counterparts, each of which when so executed and delivered to the other party shall
      be deemed an original. The executed page(s) from each original may be joined together and attached to one such original and shall thereupon constitute one and the same instrument.&#160; Such counterparts may be delivered via facsimile, electronic mail
      (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid
      and effective for all purposes.</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">***************</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">To accept this offer and all of the terms of this letter agreement, Holder must counter execute this letter agreement and return the
      fully executed letter agreement to the Company at e-mail: lalstodt@biorestorative.com, attention: Lance Alstodt, CEO, on or before the Offer Expiration Time.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Please do not hesitate to call me if you have any questions.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 216pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Sincerely yours,</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 216pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">BIORESTORATIVE THERAPIES, INC.</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 216pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">By: _______________________</div>
    <div style="text-align: justify; margin-left: 216pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Name: Lance Alstodt</div>
    <div style="text-align: justify; margin-left: 216pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Title: Chief Executive Officer</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Accepted and Agreed to:</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Name of Holder: ________________________________________________________</div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Signature of Authorized Signatory of Holder</font>:
      _________________________________</div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Name of Authorized Signatory: _______________________________________________</div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Title of Authorized Signatory: ________________________________________________</div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Existing Warrants being exercised:____________</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Aggregate Exercise Price of the Existing Warrants at the Reduced Exercise Price being exercised contemporaneously with signing this letter:
      $___________________ ($2.33 x Existing Warrants)</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">New Warrant Shares: _________________</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">New Warrant Purchase Price: $______________ ($0.125 x New Warrant Shares)</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Beneficial Ownership Limitation New Warrant: 4.99%/9.99%</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Address for Delivery of New Warrant: _________________________</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">DTC Instructions:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">The Existing Warrant Shares shall be delivered to the following DWAC Account Number:</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z1fdeea10e15e4f7baa6f204f1dd0ecb6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 27.21%; vertical-align: top;">
            <div>&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Broker Name:</div>
          </td>
          <td style="width: 2.92%; vertical-align: top;">&#160;</td>
          <td style="width: 69.87%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 27.21%; vertical-align: top;">
            <div>&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Broker DTC DWAC #:</div>
          </td>
          <td style="width: 2.92%; vertical-align: top;">&#160;</td>
          <td style="width: 69.87%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 27.21%; vertical-align: top;">
            <div>&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Broker Contact:</div>
          </td>
          <td style="width: 2.92%; vertical-align: top;">&#160;</td>
          <td style="width: 69.87%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 27.21%; vertical-align: top;">
            <div>&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Account #:</div>
          </td>
          <td style="width: 2.92%; vertical-align: top;">&#160;</td>
          <td style="width: 69.87%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"><u>Annex A &#8211; Representations and Warranties</u></div>
    <div><br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Representations, Warranties and Covenants of the Company</u></font>.&#160;
      The Company hereby makes the following representations and warranties to the Holder:</div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z3cdee213f6a94307ad8613be1652efb6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(a)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Registration Statements</u></font>.
                The Existing Warrant Shares have been registered pursuant to the Registration Statement and the Company knows of no reason why the Registration Statement shall not remain effective for the foreseeable future. The Company shall cause its
                legal counsel to provide an opinion letter to the Holder on or before the Share Delivery Deadline regarding the effectiveness of the Registration Statement and free trading status of the Common Stock to be issued pursuant to the Warrant
                Exercise. The Company shall keep the Registration Statement effective and available for use by the Holder until all Existing Warrant Shares underlying the Existing Warrants are sold by the Holder.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z4fc5a733adfd4e3eaca1cde423fa0efc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(b)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Authorization;
                    Enforcement</u></font>.&#160; The Company will have the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this letter agreement and otherwise to carry out its obligations hereunder and
                thereunder.&#160; The execution and delivery of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Company and no
                further action is required by the Company, its board of directors or its stockholders in connection therewith.&#160; This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will
                constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
                and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as
                indemnification and contribution provisions may be limited by applicable law.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zce3231f41c1d41aaadf931144e3f4952" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(c)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>No Conflicts</u></font>.&#160;
                The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company&#8217;s
                certificate of incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation
                of any Lien upon any of the properties or assets of the Company in connection with, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material
                agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company is a party or by which any property or asset of the Company is bound or affected,
                other than for which a waiver has been obtained by the Company; or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to
                which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z6277a81e0fbb47d8925fc5d280bd5632" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(d)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Nasdaq Corporate
                    Governance</u></font>. To the Company&#8217;s knowledge, the transactions contemplated under this letter agreement comply with all rules of Nasdaq.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z4e8d3c0767e04e54af3302f8d87f0840" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(e)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Issuance of the New
                    Warrant</u></font>. The issuance of the New Warrants will be duly authorized and, upon the execution of this letter agreement by the undersigned, will be duly and validly issued, fully paid and nonassessable, free and clear of all liens
                imposed by the Company, and the shares issuable upon exercise of the New Warrant (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>New Warrant Shares</u></font>&#8221;), when issued in accordance with the terms
                of the New Warrant, will be validly issued, fully paid and nonassessable, free and clear of all liens imposed by the Company. The Company will reserve from its duly authorized capital stock a number of shares of Common Stock for issuance of
                the New Warrant Shares in full.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z0e5b68c6ff8846b1b0ec7bac11647e8d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(f)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>Legends and Transfer Restrictions.</u></div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z3586203d6f0441aba8e072125aab716f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(i)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;&#160;The New Warrant and New Warrant Shares may only be disposed of in compliance with state and federal securities laws. In
                connection with any transfer of New Warrant or New Warrant Shares other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of the undersigned or in connection with a pledge, the Company may
                require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to
                the effect that such transfer does not require registration of such transferred New Warrant and New Warrant Shares under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of
                this letter agreement.</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z718d27e3dcd74e76907fddf3c77eb202" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(ii)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;&#160;The undersigned agrees to the imprinting, so long as is required by this Section (i), of a legend on any of the New Warrant
                and New Warrant Shares in the following form:</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
      COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
      REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.&#160; THIS
      SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES..</div>
    <div style="margin-bottom: 6pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 54pt;"><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 18pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">The Company acknowledges and agrees that the undersigned may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all of the New Warrant to a
        financial institution that is an &#8220;accredited investor&#8221; as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this letter agreement and, if required under the terms of such arrangement, the undersigned
        may transfer pledged or secured New Warrant to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be
        required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate undersigned&#8217;s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of New Warrant may
        reasonably request in connection with a pledge or transfer of the New Warrant or New Warrant Shares.</font></div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z75759011f8f04b17a140cd2d82ec004d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(iii)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;Certificates evidencing the New Warrant Shares shall not contain any legend (including the legend set forth in Section
                (f)(ii) hereof), (i) while a registration statement covering the resale of such security is effective under the Securities Act, (ii) following any sale of such New Warrant Shares pursuant to Rule 144,&#160; or (iii) if such New Warrant Shares
                are eligible for sale under Rule 144. The Company shall cause its counsel to issue a legal opinion to its transfer agent (if required by the transfer agent) and the undersigned (if requested by the undersigned) in connection with the
                removal of the legend hereunder. If all or any portion of a New Warrant is exercised at a time when there is an effective registration statement to cover the resale of the New Warrant Shares, or if such New Warrant Shares may be sold under
                Rule 144, then such New Warrant Shares shall be issued free of all legends. The Company agrees that following such time as such legend is no longer required under this clause (iii), it will, no later than the earlier of (i) two (2) Trading
                Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by Holder to the Company or the Transfer Agent of a certificate representing Warrant Shares, as applicable, issued
                with a restrictive legend (such date, the &#8220;Legend Removal Date&#8221;), deliver or cause to be delivered to the undersigned a certificate representing such shares that is free from all restrictive and other legends. The Company may not make any
                notation on its records or give instructions to the transfer agent that enlarge the restrictions on transfer set forth in this Section (f). Certificates for New Warrant Shares subject to legend removal hereunder shall be transmitted by the
                transfer agent to the undersigned by crediting the account of the undersigned&#8217;s prime broker with the Depository Trust Company System as directed by the undersigned. &#8220;Standard Settlement Period&#8221; means the standard settlement period,
                expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of a certificate representing Warrant Shares issued with a restrictive legend.</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zdb6e0c58024f46e092baed232833b70e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(iv)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;&#160;In addition to such undersigned&#8217;s other available remedies, the Company shall pay to the undersigned, in cash, (i) as
                partial liquidated damages and not as a penalty, for each $1,000 of New Warrant Shares (based on the VWAP of the Common Stock on the date such Securities are submitted to the Transfer Agent) delivered for removal of the restrictive legend
                and subject to Section (f)(iii), $10 per Trading Day (increasing to $20 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate is delivered
                without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to the undersigned by the Legend Removal Date a certificate representing the Securities so delivered to the Company by such undersigned that
                is free from all restrictive and other legends and (b) if after the Legend Removal Date such undersigned purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such undersigned
                of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock that such undersigned anticipated receiving from the Company
                without any restrictive legend, then, an amount equal to the excess of such undersigned&#8217;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including
                brokerage commissions and other out-of-pocket expenses, if any) (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Buy-In Price</u></font>&#8221;) over the product of (A) such number of New Warrant Shares that
                the Company was required to deliver to such undersigned by the Legend Removal Date multiplied by (B) the lowest closing sale price of the Common Stock on any Trading Day during the period commencing on the date of the delivery by such
                undersigned to the Company of the applicable New Warrant Shares (as the case may be) and ending on the date of such delivery and payment under this clause (ii).</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: left; margin-left: 0.05pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"> </font><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z284e06c8642a4314ae38db8d7af65fc4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(g)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Public Information Failure</u></font>. At any
                time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of the New Warrant Shares may be sold without the requirement for the Company to be in compliance with Rule 144(c)(1)
                and otherwise without restriction or limitation pursuant to Rule 144, if there is no effective registration statement covering the resale of all of the New Warrant Shares and the Company (i) shall fail for any reason to satisfy the current
                public information requirement under Rule 144(c) or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes an issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) (a &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Public Information Failure</u></font>&#8221;) then, in addition to the undersigned&#8217;s other available remedies, the Company shall pay to the undersigned, in cash, as
                partial liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the New Warrant Shares, an amount in cash equal to two percent (2.0%) of the aggregate Exercise Price of the undersigned&#8217;s
                New Warrant on the day of a Public Information Failure and on every thirtieth (30th) day (pro-rated for periods totaling less than thirty days) thereafter until the earlier of (a) the date such Public Information Failure is cured and (b)
                such time that such public information is no longer required&#160; for the undersigned to transfer the New Warrant Shares pursuant to Rule 144.&#160; The payments to which the undersigned shall be entitled pursuant to this Section (g) are referred to
                herein as &#8220;Public Information Failure Payments.&#8221; Public Information Failure Payments shall be paid on the earlier of (i) the last day of the calendar month during which such Public Information Failure Payments are incurred and (ii) the
                third (3rd) Business Day after the event or failure giving rise to the Public Information Failure Payments is cured.&#160; In the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information
                Failure Payments shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Nothing herein shall limit the undersigned&#8217;s right to pursue actual damages for the Public Information Failure, and the
                undersigned shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief.</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z00d96a4a189349a2885f14798b79d6bd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(h)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Listing of Common Stock</u></font>. The
                Company shall apply to list or quote all of the New Warrant Shares on Nasdaq and promptly secure the listing of all of the New Warrant Shares on Nasdaq.</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zd829e7df03a241e4a115a2781a4cea3a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(i)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Registration Statement</u></font>.&#160; As soon as
                practicable (and in any event within ten (10) calendar days of the date of this Agreement), the Company shall file a registration statement on Form S-3 (or other appropriate form if the Company is not then S-3 eligible) providing for the
                resale by the Holders of the New Warrant Shares issued and issuable upon exercise of the New Warrants.&#160; The Company shall use commercially reasonable efforts to cause such registration to become effective on or prior to the 30<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>
                calendar day after the initial filing date and to keep such registration statement effective at all times until no Holder owns any New Warrants or New Warrant Shares issuable upon exercise thereof.</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zc72e632178d746ebbb67dea2ae588ace" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(j)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Subsequent Equity Sales</u></font>.&#160; From the
                date hereof until 45 days following the date hereof, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock
                Equivalents or (ii) file any registration statement or any amendment or supplement thereto, in each case other than the registration statement registering the New Warrant Shares or a registration statement on Form S-8.&#160; Notwithstanding the
                foregoing, this Section (j) shall not apply in respect of an Exempt Issuance.&#160; As used herein, &#8220;Exempt Issuance&#8221; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant to any
                stock or option plan duly adopted for such purpose by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) securities upon
                the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this letter agreement,
                provided that such securities have not been amended since the date of this letter agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (except for such
                decreases in exercise, exchange or conversion price in accordance with the terms of such securities) or to extend the term of such securities, (c) upon the exercise or exchange of or conversion of any securities issued pursuant to this
                letter agreement, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as &#8220;restricted securities&#8221; (as
                defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith until the registration statement registering all of the New Warrant Shares is declared effective,
                and provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of
                the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an
                entity whose primary business is investing in securities.</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z5071a7c15fdb499eb64b126fbb44e1ae" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(k)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">From the date hereof until the one-year anniversary of the date hereof, the Company shall be prohibited from effecting or
                entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction.&#160; &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Variable Rate Transaction</u></font>&#8221; means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or
                exercisable for, or include the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies with, the trading prices of or quotations
                for the shares of Common Stock at any time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of
                such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any
                agreement, including, but not limited to, an equity line of credit or an &#8220;at-the-market offering,&#8221; whereby the Company may issue securities at a future determined price, regardless of whether shares pursuant to such agreement have actually
                been issued and regardless of whether such agreement is subsequently canceled; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font>, <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>however</u></font>, that, after the six month anniversary of the Closing Date, the entry into and/or issuance of shares of Common Stock in an &#8220;at the market&#8221; offering shall not be deemed a Variable Rate
                Transaction.&#160; The Holder shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"><u>Annex B &#8211; Form of New Warrant</u></div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(see attached)</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ex10_3.htm
<DESCRIPTION>NEW WARRANT ISSUED TO WARRANTHOLDERS (OTHER THAN AUCTUS FUND, LLC)
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Certilman Balin
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div><br>
  </div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
    SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
    UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.&#160; THIS SECURITY AND THE SECURITIES
    ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</div>
  <div style="margin-bottom: 12pt;"><br>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">COMMON STOCK PURCHASE WARRANT</div>
  <div><br>
  </div>
  <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">&#160;BIORESTORATIVE THERAPIES, INC.</div>
  <div style="text-align: left; margin-top: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">Warrant Shares: _______</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 324pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">Initial Exercise Date: February 8, 2024</font></div>
  <div style="margin-bottom: 12pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">THIS COMMON STOCK PURCHASE WARRANT (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Warrant</u></font>&#8221;)
    certifies that, for value received, _____________ or its assigns (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Holder</u></font>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the
    conditions hereinafter set forth, at any time on or after the date hereof (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Initial Exercise Date</u></font>&#8221;) and on or prior to 5:00 p.m. (New York City time) on
    February 8, 2029 (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Termination Date</u></font>&#8221;) but not thereafter, to subscribe for and purchase from BioRestorative Therapies, Inc., a Delaware corporation (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Company</u></font>&#8221;), up to ______ shares (as subject to adjustment hereunder, the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Warrant
        Shares</u></font>&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</div>
  <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Section 1</u>.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 108pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Definitions</u></font>.&#160; In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</font></div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Affiliate</u></font>&#8221;
    means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Bid Price</u></font>&#8221;
    means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding
    date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&#160; if OTCQB or OTCQX is not a Trading Market, the
    volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are
    then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&#160;in all other cases, the fair market value of a
    share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid
    by the Company.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Board of
        Directors</u></font>&#8221; means the board of directors of the Company.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Business Day</u></font>&#8221;
    means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font>,
    <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>however</u></font>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;,
    &#8220;non-essential employee&#8221;&#160; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of
    commercial banks in The City of New York generally are open for use by customers on such day.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Commission</u></font>&#8221;
    means the United States Securities and Exchange Commission.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Common Stock</u></font>&#8221;
    means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Common Stock
        Equivalents</u></font>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other
    instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Exchange Act</u></font>&#8221; means the
    Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Letter Agreement</u></font>&#8221;
    means that certain Warrant Reset and Reload Letter, dated as of February 6, 2024, by and among the Company and the holders signatory thereto.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Person</u></font>&#8221;
    means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Securities Act</u></font>&#8221;
    means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Subsidiary</u></font>&#8221;
    means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Trading Day</u></font>&#8221;
    means a day on which the Common Stock is traded on a Trading Market.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Trading Market</u></font>&#8221;
    means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
    Stock Exchange (or any successors to any of the foregoing).</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Transfer Agent</u></font>&#8221;
    means Transhare Corporation, the current transfer agent of the Company, with a mailing address of Bayside Center 1, 17755 North US Highway 19, Suite 140, Clearwater, Florida 33764, and any successor transfer agent of the Company.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>VWAP</u></font>&#8221;
    means, for any date, the price determined by the first of the following clauses that means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the
    daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York
    City time) to 4:02 p.m. (New York City time)), (b)&#160; if the OTCQB Venture Market (&#8220;OTCQB&#8221;) or the OTCQX Best Market (&#8220;OTCQX&#8221;) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on
    OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (&#8220;Pink Market&#8221;) operated by the OTC Markets, Inc. (or a
    similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&#160;in all other cases, the fair market value of a share of Common Stock as determined by an
    independent appraiser selected in good faith by the Purchasers of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Section 2</u>.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 108pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Exercise</u></font>.</font></div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z916c10969a41466a82b046f5c2745860" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">a)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Exercise of Warrant</u></font>.&#160;
              Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed
              facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Notice of Exercise</u></font>&#8221;).
              Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the
              aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in
              the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.&#160; Notwithstanding anything herein to
              the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the
              Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a
              portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased.&#160; The
              Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such
              notice.&#160; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph,
                following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zf36006796b524c06a6b0e78cb550dc97" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">b)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Exercise Price</u></font>.&#160;
              The exercise price per share of Common Stock under this Warrant shall be $2.43, subject to adjustment hereunder (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Exercise Price</u></font>&#8221;).</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="za84d3379cb624412b83f762bad01b37a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">c)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Cashless Exercise</u></font>.
              If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in
              whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</div>
          </td>
        </tr>

    </table>
  </div>
  <div style="text-align: justify; text-indent: -27pt; margin-left: 99pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of
    Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of
    &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Bloomberg</u></font>&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a
    Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise
    if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: -36pt; margin-left: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: -31.5pt; margin-left: 103.5pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the
    terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance
      with Section 3(a)(9) of the Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&#160;&#160;The Company agrees not to take any position contrary to this Section 2(c).</div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z39bb21344d2d4ee2b6f115605aad272a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 18pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">d)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Mechanics of Exercise</u></font>.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z08acb94285524ee0b73255812a1c0812" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 108pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 99pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">i.</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Delivery of Warrant Shares
                  Upon Exercise</u></font>.&#160; The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository
              Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>DWAC</u></font>&#8221;) if the Company is then a participant in such system and either (A) there
              is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations
              pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to
              which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise,
              (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the
              &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Warrant Share Delivery Date</u></font>&#8221;).&#160;&#160; Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the
              holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a
              cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise.&#160; If the Company fails for any reason to
              deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject
              to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $5 per Trading Day (increasing to $10 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each
              Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant
              remains outstanding and exercisable.&#160; As used herein, &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Standard Settlement Period</u></font>&#8221; means the standard settlement period, expressed in a number of
              Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zc2b75dd8b45040f9a2037383d6a00751" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 108pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 144pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">ii.</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 54pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Delivery of New Warrants
                  Upon Exercise</u></font>.&#160; If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the
              Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z8d60a38b58f34b07984926eb9f5b37fd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 108pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 144pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">iii.</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Rescission Rights</u></font>.&#160;
              If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zdfb3d62ffbd24e8c81f647ce585ab9bf" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 108pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 144pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">iv.</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Compensation for Buy-In on
                  Failure to Timely Deliver Warrant Shares Upon Exercise</u></font>.&#160; In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with
              the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s
              brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Buy-In</u></font>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of
              Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell
              order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such
              exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.&#160; For example, if the Holder
              purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause
              (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of
              the Company, evidence of the amount of such loss.&#160; Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or
              injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="za23ff90539f04c6bb161463b6bf4ce37" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 108pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 144pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">v.</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 54pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>No Fractional Shares or
                  Scrip</u></font>.&#160; No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.&#160; As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise,
              the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z9ad76ce073684edc8bfd0a4cba4278c0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 108pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 144pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">vi.</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Charges, Taxes and Expenses</u></font>.&#160;
              Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
              and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font>, <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>however</u></font>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise
              shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.&#160; The Company
              shall pay all costs of any legal opinion required by the Company&#8217;s transfer agent and any Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established
              clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z234b7a057246474982e3eae529b4fef5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 108pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 144pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">vii.</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Closing of Books</u></font>.&#160;
              The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="za3d3ef7be56e477788ba3841a133f190" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">e)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Holder&#8217;s Exercise
                  Limitations</u></font>.&#160; The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect
              to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such
              Persons, &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Attribution Parties</u></font>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&#160; For purposes of the
              foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to
              which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its
              Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other&#160; Common Stock Equivalents) subject to a limitation
              on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&#160; Except as set forth in the preceding sentence, for purposes of this Section 2(e),
              beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it is acknowledged by the Holder that the Company is not representing to the Holder that such
              calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.&#160;&#160; To the extent that the limitation contained in this Section 2(e)
              applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the
              sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any
              Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such
              determination.&#160; In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.&#160; For purposes of this
              Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the
              Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&#160; Upon the written or
              oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&#160; In any case, the number of outstanding shares of Common Stock shall be
              determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common
              Stock was reported.&#160; The &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Beneficial Ownership Limitation</u></font>&#8221; shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%)
              of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant.&#160; The Holder, upon notice to the Company, may increase or decrease the
              Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the
              issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply.&#160; Any increase in the Beneficial Ownership Limitation will not be effective until the 61<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup>
              day after such notice is delivered to the Company.&#160; The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any
              portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations
              contained in this paragraph shall apply to a successor holder of this Warrant.</div>
          </td>
        </tr>

    </table>
  </div>
  <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Section 3</u>.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 108pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Certain Adjustments</u></font>.</font></div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z28511651e86d4569ba46a21e1d0b4744" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">a)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Stock Dividends and Splits</u></font>.
              If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
              Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
              (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the
              Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the
              number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain
              unchanged.&#160; Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective
              immediately after the effective date in the case of a subdivision, combination or reclassification.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zae3b4788466544a599c8c9bd8e7348f7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">b)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Subsequent Rights Offerings</u></font>.&#160;
              <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase
                stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if
                the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately
                before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue
                or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be
                entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
                the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z90ed8e44485b489f98f93aa2d6f50a3b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">c)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Pro Rata Distributions</u></font>.&#160;
              During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or
              otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction)
              (a &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Distribution</u></font>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such
              Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
              hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of
              Common Stock are to be determined for the participation in such Distribution (<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font>, <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>however</u></font>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to
              participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of
              the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z64757adaebed448e994a58766f7a6722" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">d)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Fundamental Transaction</u></font>.
              If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or
              indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender
              offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by
              the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
              share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share
              purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
              acquires more than 50% of the outstanding shares of Common Stock or more than 50% of the voting power of the common equity of the Company (each a &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Fundamental
                  Transaction</u></font>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such
              Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it
              is the surviving corporation, and any additional consideration (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Alternate Consideration</u></font>&#8221;) receivable as a result of such Fundamental Transaction
              by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).&#160; For purposes of
              any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such
              Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.&#160; If holders of
              Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this
              Warrant following such Fundamental Transaction.&#160; Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any
              time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">purchase this Warrant from the Holder by paying to the Holder</font> an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the
              consummation of such Fundamental Transaction; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font>,<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>however</u></font>, that, if the Fundamental Transaction is not within the Company's control, including not approved by the Company's Board of
              Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is
              being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock
              are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font>, <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>further</u></font>, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common
              Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.&#160; &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Black Scholes Value</u></font>&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg, L.P. (&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Bloomberg</u></font>&#8221;) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury
              rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of the greater of (1) the 30 day
              volatility, (2) the 100 day volatility or (3) the 365 day volatility, each of clauses (1)-(3) as obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the
              public announcement of the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value
              of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable contemplated
              Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder&#8217;s request pursuant to this Section 3(d) and (D) a remaining option time equal to the time between
              the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow.&#160; The payment of the Black Scholes Value will be made by wire transfer of immediately available
              funds (or such other consideration) within five Business Days of the Holder&#8217;s election (or, if later, on the date of consummation of the Fundamental Transaction).&#160; The Company shall cause any successor entity in a Fundamental Transaction in
              which the Company is not the survivor (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Successor Entity</u></font>&#8221;) to assume in writing all of the obligations of the Company under this Warrant in
              accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and
              shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a
              corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the
              exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
              pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to
              the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted
              for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall
              assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zc4f22129ee5d4014a281c6ab9699374c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">e)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Calculations</u></font>.
              All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a
              given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z7a0ac6d755d94e8690d3addf34a50f58" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">f)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Notice to Holder</u></font>.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z7a85d61e6085497eb5132229299a207d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 108pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 144pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">i.</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 54pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Adjustment to Exercise
                  Price</u></font>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment
              and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z268fa375b3a94d99844592d4e3493bdd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 108pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 144pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">ii.</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 54pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Notice to Allow Exercise by
                  Holder</u></font>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock,
              (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company
              shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any
              compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
              then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the
              applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the
              date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale,
              transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or
              other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of
              the corporate action required to be specified in such notice.&#160; To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company
              shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.&#160; The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of
              the event triggering such notice except as may otherwise be expressly set forth herein.</div>
          </td>
        </tr>

    </table>
  </div>
  <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Section 4</u>.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 108pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Transfer of Warrant</u></font>.</font></div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z9739965441f14d4396d2fa9e99554467" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">a)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Transferability</u></font>.&#160;
              Subject to compliance with applicable securities laws and and the conditions set forth in Section 4(d) hereof and Section (f) of <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Annex A</u></font> to the Letter
              Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent,
              together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.&#160; Upon
              such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of
              assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.&#160; Notwithstanding anything herein to the contrary, the Holder shall not be required
              to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder
              delivers an assignment form to the Company assigning this Warrant in full.&#160; The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z33364d7371094eb7b9faa184b25b1322" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">b)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>New Warrants</u></font>.
              This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed
              by the Holder or its agent or attorney.&#160; Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the
              Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the
              number of Warrant Shares issuable pursuant thereto.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z69f74a16d6654150ba773246c212e52d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">c)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Warrant Register</u></font>.
              The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Warrant Register</u></font>&#8221;), in the name of the
              record Holder hereof from time to time.&#160; The Company and the Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all
              other purposes, absent actual notice to the contrary.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zbd1513e84aee45adaf4d647e98954de3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">d)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Transfer Restrictions</u></font>.
              <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or
                current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, </font>provides to the Company an opinion
              of counsel, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that the transfer of this Warrant does not require registration under the Securities Act.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zf4d6000a098c4aac8e7ed15652a06efb" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">e)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Representation by the
                  Holder</u></font>.&#160; The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not
              with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</div>
          </td>
        </tr>

    </table>
  </div>
  <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Section 5</u>.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 108pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Miscellaneous</u></font>.</font></div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zb27a25d55de64e5fa34bc09d28771ffb" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">a)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>No Rights as Stockholder
                  Until Exercise; No Settlement in Cash</u></font>.&#160; This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i),
              except as expressly set forth in Section 3.&#160; Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv)
              herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zd7aab140d464434eaa338dd1fd6de5c8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">b)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Loss, Theft, Destruction or
                  Mutilation of Warrant</u></font>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the
              Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such
              Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z4aee761264d44faf8fa2df8794fc20b3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">c)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Saturdays, Sundays,
                  Holidays, etc</u></font>.&#160; If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the
              next succeeding Trading Day.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z21dc7504971f4cfeb27dcabad1fbc7bf" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">d)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Authorized Shares</u></font>.</div>
          </td>
        </tr>

    </table>
  </div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its
    authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.&#160; The Company further covenants that its issuance of this Warrant shall
    constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.&#160; The Company will take all such reasonable action as may be necessary to assure
    that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.&#160; The Company covenants that all Warrant Shares
    which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
    issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any
    action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid
    the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder
    as set forth in this Warrant against impairment.&#160; Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such
    increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
    reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Before taking any action which would result in an adjustment in the number of Warrant Shares for
    which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z4054f7d535ff4e72930ece0997823f1a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">e)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Governing Law</u></font>.
              All questions <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance
                with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
                contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
                sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in
                connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction
                of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
                action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall
                constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action,
                suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&#8217; fees and other costs and expenses incurred with the
                investigation, preparation and prosecution of such action or proceeding</font>.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z462bf86b26634fd78b1a2fc7bbea0aad" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">f)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Restrictions</u></font>.&#160;
              The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z4d1454ac229a4142bd420772f3798682" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">g)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Nonwaiver and Expenses</u></font>.&#160;
              No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies.&#160; Without limiting any other provision
              of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover
              any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights,
              powers or remedies hereunder.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z5ed04625931c4f4b887220115d771e4c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">h)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Notices</u></font>.&#160; Any
              and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized
              overnight courier service, addressed to the Company, at 40 Marcus Drive, Suite One, Melville, New York 11747, Attention:<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</font>Chief Executive
              Officer, email address: lalstodt@biorestorative.com, or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the
              Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the
              Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in
              this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that
              is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by
              the party to whom such notice is required to be given.&#160; To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously
              file such notice with the Commission pursuant to a Current Report on Form 8-K.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zcad7d4a93a374ad59bf77f022217b195" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">i)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Limitation of Liability</u></font>.&#160;
              No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
              Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zf1ca5e8fc3904a0da3efb219e2f9d96a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">j)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Remedies</u></font>.&#160; In
              addition to being entitled to exercise all rights granted by law, including recovery of damages, the Holder will be entitled to specific performance of its rights under this Warrant.&#160; The Company agrees that monetary damages would not be
              adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z720b1228f3334f6bba3fcab89c42626b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">k)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Successors and Assigns</u></font>.&#160;
              Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
              of Holder.&#160; The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="z5846e1e6ecf34731bff30056ccc96bbf" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">l)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Amendment</u></font>.&#160; This
              Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">and the Holder, on the other hand</font>.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="za0b3500728e74dd2b4b7d8b78cbbc79c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">m)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Severability</u></font>.&#160;
              Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
              provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zd6e31b56dcd44e53a814b37115adf0c1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; text-align: right;">
            <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">n)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Headings</u></font>.&#160; The
              headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</div>
          </td>
        </tr>

    </table>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">********************</div>
  <div><br>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-style: italic;">(Signature Page Follows)</div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of
    the date first above indicated.</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 180pt;"><br>
  </div>
  <table cellspacing="0" cellpadding="0" id="z8b1827682a87426d9a565ca5d012ac2e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

      <tr>
        <td style="width: 100%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">BIORESTORATIVE THERAPIES, INC.</div>
          <div>&#160;</div>
          <div>&#160;</div>
        </td>
      </tr>
      <tr>
        <td style="width: 100%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">By:__________________________________________</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;Name: Lance Alstodt</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;Title: President and Chief Executive Officer</div>
          <div>&#160;</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div><br>
  </div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div><br>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">NOTICE OF EXERCISE</div>
  <div><br>
  </div>
  <div style="text-align: justify;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">TO:</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">BIORESTORATIVE THERAPIES, INC.</font></div>
  <div><br>
  </div>
  <div style="margin-bottom: 12pt; text-indent: 72pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(1)</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith
      payment of the exercise price in full, together with all applicable transfer taxes, if any.</font></div>
  <div style="margin-bottom: 12pt; text-indent: 72pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(2)</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">Payment shall take the form of (check applicable box):</font></div>
  <div style="text-align: justify; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">[&#160; ] in lawful money of the United States; or</div>
  <div style="text-align: justify; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">[ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula
    set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</div>
  <div style="margin-bottom: 12pt; text-indent: 72pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(3)</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</font></div>
  <div style="text-align: justify; text-indent: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">_______________________________</div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">The Warrant Shares shall be delivered to the following DWAC Account Number:</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">_______________________________</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">_______________________________</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">_______________________________</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(4)&#160; Accredited Investor.&#160; The undersigned is an &#8220;accredited investor&#8221; as defined in Regulation D promulgated under the Securities Act of
    1933, as amended.</div>
  <div><br>
  </div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">[SIGNATURE OF HOLDER]</div>
  <div><br>
  </div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Name of Investing Entity: ________________________________________________________________________</div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Signature of Authorized Signatory of Investing Entity</font>:
    _________________________________________________</div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Name of Authorized Signatory: ___________________________________________________________________</div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Title of Authorized Signatory: ____________________________________________________________________</div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Date: ________________________________________________________________________________________</div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="margin-bottom: 12pt;"><br>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">ASSIGNMENT FORM</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 10.5pt; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-style: italic;">(To assign the foregoing Warrant, execute this form and supply required information.&#160; Do not use
    this form to purchase shares.)</div>
  <div style="text-align: justify; text-indent: 10.5pt; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</div>
  <table cellspacing="0" cellpadding="0" id="zfc37216604ae47d498d6710de1a4aab7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

      <tr>
        <td style="width: 50%; vertical-align: top;">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Name:</div>
        </td>
        <td style="width: 50%; vertical-align: top;">&#160;</td>
      </tr>
      <tr>
        <td style="width: 50%; vertical-align: top;">&#160;</td>
        <td style="width: 50%; vertical-align: top;">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(Please Print)</div>
        </td>
      </tr>
      <tr>
        <td style="width: 50%; vertical-align: top;">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Address:</div>
        </td>
        <td style="width: 50%; vertical-align: top;">&#160;</td>
      </tr>
      <tr>
        <td style="width: 50%; vertical-align: top;">
          <div>&#160;</div>
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Phone Number:</div>
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Email Address:</div>
        </td>
        <td style="width: 50%; vertical-align: top;">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(Please Print)</div>
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">______________________________________</div>
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">______________________________________</div>
        </td>
      </tr>
      <tr>
        <td style="width: 50%; vertical-align: top;">
          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Dated: _______________ __, ______</div>
        </td>
        <td style="width: 50%; vertical-align: top;">&#160;</td>
      </tr>
      <tr>
        <td style="width: 50%; vertical-align: top;">
          <div style="text-align: justify;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">Holder&#8217;s Signature:</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 214.5pt">&#160;</font></div>
        </td>
        <td style="width: 50%; vertical-align: top;">&#160;</td>
      </tr>
      <tr>
        <td style="width: 50%; vertical-align: top;">
          <div style="text-align: justify;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">Holder&#8217;s Address:</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 214.5pt">&#160;</font></div>
        </td>
        <td style="width: 50%; vertical-align: top;">&#160;</td>
      </tr>

  </table>
  <div style="margin-bottom: 12pt;"><br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>ex10_4.htm
<DESCRIPTION>NEW WARRANT ISSUED TO AUCTUS FUND, LLC
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Certilman Balin
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
      SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
      STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.&#160; THIS SECURITY AND THE
      SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</div>
    <div style="margin-bottom: 12pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">COMMON STOCK PURCHASE WARRANT</div>
    <div><br>
    </div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">&#160;BIORESTORATIVE THERAPIES, INC.</div>
    <div style="text-align: left; margin-top: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">Warrant Shares: _______</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 324pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">Initial Exercise Date: February 8, 2024</font></div>
    <div style="margin-bottom: 12pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">THIS COMMON STOCK PURCHASE WARRANT (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Warrant</u></font>&#8221;) certifies that, for value received, _____________ or its assigns (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Holder</u></font>&#8221;) is entitled, upon the terms and subject to
      the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Initial Exercise Date</u></font>&#8221;) and on or prior to
      5:00 p.m. (New York City time) on February 8, 2029 (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Termination Date</u></font>&#8221;) but not thereafter, to subscribe for and purchase from BioRestorative Therapies,
      Inc., a Delaware corporation (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Company</u></font>&#8221;), up to ______ shares (as subject to adjustment hereunder, the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Warrant Shares</u></font>&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Section 1</u>.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 108pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Definitions</u></font>.&#160; In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</font></div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Affiliate</u></font>&#8221;
      means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Bid Price</u></font>&#8221;
      means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on
      the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&#160; if the Common Stock is quoted for trading on the
      OTCQB or OTCQX, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is quoted for trading on the OTC Markets Pink Open Market (or a similar
      organization or agency succeeding to its functions of reporting prices) (the &#8220;Pink Market&#8221;), the most recent bid price per share of the Common Stock so reported, or (d)&#160;in all other cases, the fair market value of a share of Common Stock as
      determined by an independent appraiser selected in good faith by the holders of a majority in interest of this Warrant then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Board of
          Directors</u></font>&#8221; means the board of directors of the Company.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Business Day</u></font>&#8221;
      means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font>,
      <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>however</u></font>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;,
      &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221;&#160; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for
      wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Commission</u></font>&#8221;
      means the United States Securities and Exchange Commission.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Common Stock</u></font>&#8221;
      means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Common Stock
          Equivalents</u></font>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other
      instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Exchange Act</u></font>&#8221; means the
      Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Letter
          Agreement</u></font>&#8221; means that certain Warrant Reset and Reload Letter, dated as of February 6, 2024, by and among the Company and the holders signatory thereto.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Person</u></font>&#8221;
      means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Securities Act</u></font>&#8221;
      means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Subsidiary</u></font>&#8221;
      means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Trading Day</u></font>&#8221;
      means a day on which the Common Stock is traded on a Trading Market, the OTCQX, the OTCQB, the Pink Market, or any other principal marketplace on which the Common Stock is then traded.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Trading Market</u></font>&#8221;
      means any of the following markets or exchanges on which the Common Stock is listed for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock
      Exchange (or any successors to any of the foregoing).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Transfer Agent</u></font>&#8221;
      means Transhare Corporation, the current transfer agent of the Company, with a mailing address of Bayside Center 1, 17755 North US Highway 19, Suite 140, Clearwater, Florida 33764, and any successor transfer agent of the Company.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>VWAP</u></font>&#8221;
      means, for any date, the price determined by the first of the following clauses that means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed on a Trading Market, the daily
      volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
      time) to 4:02 p.m. (New York City time)), (b)&#160; if the Common Stock is quoted for trading on the OTCQB or OTCQX, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)
      if the Common Stock is quoted for trading on the Pink Market, the most recent bid price per share of the Common Stock so reported, or (d)&#160;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
      selected in good faith by the holders of a majority in interest of this Warrant then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Section 2</u>.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 108pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Exercise</u></font>.</font></div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z8fde8aefccae402b8d254fca6f4b6b79" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">a)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Exercise of Warrant</u></font>.&#160;
                Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed
                facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Notice of Exercise</u></font>&#8221;).
                Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver to the
                Company the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c)
                below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.&#160;
                Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been
                exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this
                Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable
                number of Warrant Shares purchased.&#160; The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver to the Holder any objection to any Notice of
                Exercise within one (1) Trading Day of receipt of such notice.&#160; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">The Holder and any assignee, by acceptance of this Warrant, acknowledge and
                  agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount
                  stated on the face hereof.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z9a34bf193794457eb321b8d9c7404790" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">b)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Exercise Price</u></font>.&#160;
                The exercise price per share of Common Stock under this Warrant shall be $2.43, subject to adjustment hereunder (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Exercise Price</u></font>&#8221;).</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zb7716159849e41f39b433b1868c26ed3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">c)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Cashless Exercise</u></font>.
                If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in
                whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; text-indent: -27pt; margin-left: 99pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of
      Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of
      &#8220;regular trading hours&#8221; (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of
      the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Bloomberg</u></font>&#8221;) as of
      the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the
      close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof, or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both
      executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: -36pt; margin-left: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: -31.5pt; margin-left: 103.5pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the
      terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance
        with Section 3(a)(9) of the Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&#160;&#160;The Company agrees not to take any position contrary to this Section 2(c).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically
      exercised via cashless exercise pursuant to this Section 2(c).</div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zffd02a204cfe4fd498d01eec0f543e72" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 18pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">d)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Mechanics of Exercise</u></font>.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z3d67ad9b92e5493da1edac0d66c7fcbc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 108pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 99pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">i.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Delivery of Warrant
                    Shares Upon Exercise</u></font>.&#160; The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The
                Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>DWAC</u></font>&#8221;) if the Company is then a participant in such system and
                either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or
                manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of this Warrant), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the
                number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the
                Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of
                the Notice of Exercise (such date, the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Warrant Share Delivery Date</u></font>&#8221;).&#160;&#160; Upon delivery of the Notice of Exercise, the Holder shall be deemed for all
                corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise
                Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise.&#160; If
                the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for
                each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $5 per Trading Day (increasing to $10 per Trading Day on the fifth Trading Day after such
                liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant
                in the FAST program so long as this Warrant remains outstanding and exercisable.&#160; As used herein, &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Standard Settlement Period</u></font>&#8221; means the standard
                settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z8ae126188b7542f28e8b5aecca3d4c3e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 108pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 144pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">ii.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 54pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Delivery of New Warrants
                    Upon Exercise</u></font>.&#160; If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the
                Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z12ee1bfc7cb14b23a827e0b2448c6a01" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 108pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 144pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">iii.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Rescission Rights</u></font>.&#160;
                If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z25e51c228a30459f90d63b4bbaeec0dd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 108pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 144pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">iv.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Compensation for Buy-In
                    on Failure to Timely Deliver Warrant Shares Upon Exercise</u></font>.&#160; In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance
                with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the
                Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Buy-In</u></font>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for
                the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at
                which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
                which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.&#160; For
                example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of
                $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the
                Buy-In and, upon request of the Company, evidence of the amount of such loss.&#160; Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
                of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z46e9243711324d0ab19169bbef904e72" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 108pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 144pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">v.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 54pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>No Fractional Shares or
                    Scrip</u></font>.&#160; No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.&#160; As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such
                exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z2cd780252000411ca250ac6c1ce5cf88" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 108pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 144pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">vi.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Charges, Taxes and
                    Expenses</u></font>.&#160; Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses
                shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font>,
                <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>however</u></font>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
                exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.&#160;
                The Company shall pay all costs of any legal opinion required by the Company&#8217;s transfer agent and any Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another
                established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z57ac009512b44e5989b55061325aeb4d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 108pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 144pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">vii.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Closing of Books</u></font>.&#160;
                The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zef54787a23e640ca852f1837daf2ca5a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">e)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Holder&#8217;s Exercise
                    Limitations</u></font>.&#160; The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving
                effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates
                (such Persons, &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Attribution Parties</u></font>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&#160; For purposes of
                the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect
                to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of
                its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other&#160; Common Stock Equivalents) subject to a
                limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&#160; Except as set forth in the preceding sentence, for purposes of this Section
                2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it is acknowledged by the Holder that the Company is not representing to the Holder
                that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.&#160;&#160; To the extent that the limitation contained in this Section
                2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be
                in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any
                Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such
                determination.&#160; In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.&#160; For purposes of this
                Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the
                Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&#160; Upon the written
                or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&#160; In any case, the number of outstanding shares of Common Stock shall be
                determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common
                Stock was reported.&#160; The &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Beneficial Ownership Limitation</u></font>&#8221; shall be 9.99% of the number of shares of the Common Stock outstanding immediately after
                giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant.&#160; The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided
                that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the
                Holder and the provisions of this Section 2(e) shall continue to apply.&#160; Any increase in the Beneficial Ownership Limitation will not be effective until the 61<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> day after such notice is delivered to the Company.&#160; The provisions
                of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the
                intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of
                this Warrant.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Section 3</u>.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 108pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Certain Adjustments</u></font>.</font></div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z9da05c83ff06432588eac434874c5c50" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">a)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Stock Dividends and
                    Splits</u></font>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent
                securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger
                number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of
                the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of
                which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise
                Price of this Warrant shall remain unchanged.&#160; Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or
                distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z4169002e0c1a495899b0892cbec297ef" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">b)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Subsequent Rights
                    Offerings</u></font>.&#160; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock
                  Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase
                  Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
                  the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of
                  Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the
                  Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and
                  such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z550b3c13828146599ef89bef4588103d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">c)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Pro Rata Distributions</u></font>.&#160;
                During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or
                otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar
                transaction) (a &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Distribution</u></font>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate
                in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on
                exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of
                shares of Common Stock are to be determined for the participation in such Distribution (<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font>, <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>however</u></font>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be
                entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for
                the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z15ab5bdbea7547cd84b3bdf96f477c15" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">d)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Fundamental Transaction</u></font>.
                If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or
                indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender
                offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by
                the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
                share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or
                share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
                acquires more than 50% of the outstanding shares of Common Stock or more than 50% of the voting power of the common equity of the Company (each a &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Fundamental
                    Transaction</u></font>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of
                such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company,
                if it is the surviving corporation, and any additional consideration (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Alternate Consideration</u></font>&#8221;) receivable as a result of such Fundamental
                Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).&#160; For
                purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
                in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.&#160; If
                holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise
                of this Warrant following such Fundamental Transaction.&#160; Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable
                at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">purchase this Warrant from the Holder by paying to the Holder</font> an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant
                on the date of the consummation of such Fundamental Transaction; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font>,<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>however</u></font>, that, if the Fundamental Transaction is not within the Company's control, including not approved by
                the Company's Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion
                of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether
                the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font>,
                <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>further</u></font>, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of
                Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.&#160; &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Black Scholes Value</u></font>&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg, L.P. (&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Bloomberg</u></font>&#8221;) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S.
                Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of the greater of (1)
                the 30 day volatility, (2) the 100 day volatility or (3) the 365 day volatility, each of clauses (1)-(3) as obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately
                following the public announcement of the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any,
                plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable
                contemplated Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder&#8217;s request pursuant to this Section 3(d) and (D) a remaining option time equal to
                the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow.&#160; The payment of the Black Scholes Value will be made by wire transfer of
                immediately available funds (or such other consideration) within five Business Days of the Holder&#8217;s election (or, if later, on the date of consummation of the Fundamental Transaction).&#160; The Company shall cause any successor entity in a
                Fundamental Transaction in which the Company is not the survivor (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Successor Entity</u></font>&#8221;) to assume in writing all of the obligations of the Company
                under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such
                Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this
                Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
                regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
                value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic
                value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor
                Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and may exercise every
                right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.&#160; For the avoidance of doubt, the Holder shall be
                entitled to the benefits of the provisions of this Section 3(e) regardless of whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z494c0d23aa514ceaa85b5223985ce00e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">e)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Calculations</u></font>.
                All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a
                given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zc727a0dacb41415995b9ef40369a8dc5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">f)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Notice to Holder</u></font>.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zaa8f728d7d7045eab002bd236dd4857f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 108pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 144pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">i.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 54pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Adjustment to Exercise
                    Price</u></font>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such
                adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z79a116a0beed4d0ca71bf2a799278376" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 108pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 144pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">ii.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 54pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Notice to Allow Exercise
                    by Holder</u></font>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
                Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the
                Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets,
                or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the
                Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days
                prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to
                be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
                merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for
                securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not
                affect the validity of the corporate action required to be specified in such notice.&#160; To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the
                Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.&#160; The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice
                to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Section 4</u>.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 108pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Transfer of Warrant</u></font>.</font></div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z15b7a0e6c0ca4fa1abf6ea840e340dd0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">a)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Transferability</u></font>.&#160;
                Subject to compliance with applicable securities laws and and the conditions set forth in Section 4(d) hereof and Section (f) of <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Annex A</u></font> to the
                Letter Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated
                agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such
                transfer.&#160; Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in
                such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.&#160; Notwithstanding anything herein to the contrary, the Holder
                shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date
                on which the Holder delivers an assignment form to the Company assigning this Warrant in full.&#160; The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a
                new Warrant issued.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z2bd02a2ab2e24b7cad9536b5423476e0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">b)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>New Warrants</u></font>.
                This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
                signed by the Holder or its agent or attorney.&#160; Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange
                for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as
                to the number of Warrant Shares issuable pursuant thereto.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zd03823981992466c9a05141c20cbf78d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">c)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Warrant Register</u></font>.
                The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Warrant Register</u></font>&#8221;), in the name of the
                record Holder hereof from time to time.&#160; The Company and the Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all
                other purposes, absent actual notice to the contrary.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z55937829902146e6b34a6bd375fb23bb" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">d)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Transfer Restrictions</u></font>.
                <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions
                  or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, </font>provides to the Company an
                opinion of counsel, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that the transfer of this Warrant does not require registration under the Securities Act.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zab145fb4e6da4ddcaf198abcd184347b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">e)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Representation by the
                    Holder</u></font>.&#160; The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not
                with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Section 5</u>.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 108pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Miscellaneous</u></font>.</font></div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z7730695c61d747a68300aba0633fe5ab" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">a)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>No Rights as Stockholder
                    Until Exercise; No Settlement in Cash</u></font>.&#160; This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i),
                except as expressly set forth in Section 3.&#160; Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv)
                herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zce1b79f66e514fcaacdf46af48312d17" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">b)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Loss, Theft, Destruction
                    or Mutilation of Warrant</u></font>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the
                Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such
                Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z2c35fc9e1ec149bd9b018f74058e7063" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">c)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Saturdays, Sundays,
                    Holidays, etc</u></font>.&#160; If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on
                the next succeeding Trading Day.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zd0a33a8395a34af0b5414c4619841003" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">d)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Authorized Shares</u></font>.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from
      its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.&#160; The Company further covenants that its issuance of this Warrant
      shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.&#160; The Company will take all such reasonable action as may be necessary
      to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.&#160; The Company covenants that all Warrant
      Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized,
      validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any
      action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid
      the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of
      Holder as set forth in this Warrant against impairment.&#160; Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to
      such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
      reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Before taking any action which would result in an adjustment in the number of Warrant Shares for
      which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z9f411187c7a647f6b7bd70d4461a6501" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">e)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Governing Law</u></font>.
                All questions <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance
                  with the internal laws of the State of Delaware, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
                  contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
                  sitting in the City of New York, Borough of Manhattan. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in City of New York, Borough of Manhattan for the adjudication of any
                  dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
                  subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process
                  being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant
                  and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If
                  either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&#8217; fees and
                  other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding</font>.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z33c7e1279df04669826c4f53d9220e9e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">f)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Restrictions</u></font>.&#160;
                The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities
                laws.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zd21ed1ae4b884a17b4b2daa72f0fb124" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">g)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Nonwaiver and Expenses</u></font>.&#160;
                No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies.&#160; Without limiting any other provision
                of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to
                cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its
                rights, powers or remedies hereunder.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zb68e47d8847e482b880dcd76429c0c80" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">h)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Notices</u></font>.&#160; Any
                and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized
                overnight courier service, addressed to the Company, at 40 Marcus Drive, Suite One, Melville, New York 11747, Attention:<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</font>Chief Executive
                Officer, email address: lalstodt@biorestorative.com, or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by
                the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of
                the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set
                forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on
                a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon
                actual receipt by the party to whom such notice is required to be given.&#160; To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company
                shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zd3ed7a4a20e1420ba159f17a1175e43e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">i)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Limitation of Liability</u></font>.&#160;
                No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
                Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z0633fd2848e24e64a856b00ee8834bc8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">j)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Remedies</u></font>.&#160; In
                addition to being entitled to exercise all rights granted by law, including recovery of damages, the Holder will be entitled to specific performance of its rights under this Warrant.&#160; The Company agrees that monetary damages would not be
                adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be
                adequate.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zd025b2e674cc4f1eb873fb73d6e01d71" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">k)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Successors and Assigns</u></font>.&#160;
                Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
                assigns of Holder.&#160; The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z6f1bf2b4cfb24d1eb7d2a083690e1257" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">l)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Amendment</u></font>.&#160;
                This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">and the Holder, on the other
                  hand</font>.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z4466184edf1447c1a0704c4296332085" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">m)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Severability</u></font>.&#160;
                Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
                provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z9caec61884684d3e9fe31890e1f78ab1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">n)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Headings</u></font>.&#160; The
                headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">********************</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-style: italic;">(Signature Page Follows)</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as
      of the date first above indicated.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 180pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z80c86393f4544843b3fa10e464fb1f43" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">BIORESTORATIVE THERAPIES, INC.</div>
            <div>&#160;</div>
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">By:__________________________________________</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;Name: Lance Alstodt</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;Title: President and Chief Executive Officer</div>
            <div>&#160;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">NOTICE OF EXERCISE</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">TO:</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">BIORESTORATIVE THERAPIES, INC.</font></div>
    <div><br>
    </div>
    <div style="margin-bottom: 12pt; text-indent: 72pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(1)</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith
        payment of the exercise price in full, together with all applicable transfer taxes, if any.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 72pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(2)</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">Payment shall take the form of (check applicable box):</font></div>
    <div style="text-align: justify; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">[&#160; ] in lawful money of the United States; or</div>
    <div style="text-align: justify; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">[ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula
      set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</div>
    <div style="margin-bottom: 12pt; text-indent: 72pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(3)</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</font></div>
    <div style="text-align: justify; text-indent: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">_______________________________</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">The Warrant Shares shall be delivered to the following DWAC Account Number:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">_______________________________</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">_______________________________</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">_______________________________</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(4)&#160; Accredited Investor.&#160; The undersigned is an &#8220;accredited investor&#8221; as defined in Regulation D promulgated under the Securities Act
      of 1933, as amended.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">[SIGNATURE OF HOLDER]</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Name of Investing Entity: ________________________________________________________________________</div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Signature of Authorized Signatory of Investing Entity</font>:
      _________________________________________________</div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Name of Authorized Signatory: ___________________________________________________________________</div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Title of Authorized Signatory: ____________________________________________________________________</div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Date: ________________________________________________________________________________________</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="margin-bottom: 12pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">ASSIGNMENT FORM</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 10.5pt; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-style: italic;">(To assign the foregoing Warrant, execute this form and supply required information.&#160; Do not
      use this form to purchase shares.)</div>
    <div style="text-align: justify; text-indent: 10.5pt; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</div>
    <table cellspacing="0" cellpadding="0" id="z894cc06396f245358cf1842e6e0cd3b3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Name:</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(Please Print)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Address:</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div>&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Phone Number:</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Email Address:</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(Please Print)</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">______________________________________</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">______________________________________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Dated: _______________ __, ______</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">Holder&#8217;s Signature:</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 214.5pt">&#160;</font></div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">Holder&#8217;s Address:</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 214.5pt">&#160;</font></div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div style="margin-bottom: 12pt;"><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ex99_1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Certilman Balin
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 14pt;">BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million
        Gross Proceeds Priced At-the-Market</div>
    <div style="margin-bottom: 8pt;"><br>
    </div>
    <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MELVILEE, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) &#8211; BioRestorative Therapies, Inc. ("BioRestorative" or the &#8220;Company&#8221;) (NASDAQ:
        BRTX), a&#160; clinical stage company focused on stem cell-based therapies, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 3,351,580 shares of its common stock, in the aggregate, to exercise
        their warrants at a reduced exercise price of $2.33 per share, in exchange for new warrants as described below.&#160; The aggregate gross proceeds from the exercise of the existing warrants and the payment of the new warrants, as described below, is
        expected to total approximately $8.1 million, before deducting financial advisory fees. The reduction of the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules.</div>
    <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Roth Capital Partners is acting as the Company&#8217;s financial advisor for this transaction.</div>
    <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The shares of common stock issuable upon exercise of the warrants are registered for issuance pursuant to a registration
        statement on Form S-1, as amended (File No. 333-258611), which was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) on November 4, 2021 or for resale pursuant to a registration statement on Form S-3 (File No. 333-265052), which
        was declared effective by the SEC on June 16, 2022.</div>
    <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In consideration for the immediate exercise of the warrants for cash and the payment of $0.125 per share underlying the new
        warrants, the exercising holders will receive new warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "1933 Act").&#160; The new warrants will be exercisable into
        an aggregate of up to 2,513,685 shares of common stock, at an exercise price of $2.43 per share and have a term of exercise equal to five years.&#160; The securities offered in the private placement have not been registered under the Securities Act of
        1933, as amended, or applicable under state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration
        requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company has agreed to file a resale registration statement on Form S-3 with the Securities and Exchange Commission within 10 days of the
        closing to register the resale of the shares of common stock underlying the new warrants issued in the private placement.</div>
    <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there
        be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.</div>
    <div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: left; margin-top: 12pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About BioRestorative Therapies, Inc.</div>
      <div><br>
      </div>
    </div>
    <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols,
        primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:</font></div>
    <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226; Disc/Spine Program (brtxDISC&#8482;): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person&#8217;s
      own) cultured mesenchymal stem cells collected from the patient&#8217;s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The
      BRTX-100 production process utilizes proprietary technology and involves collecting a patient&#8217;s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected
      by a physician into the patient&#8217;s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using
      BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.</div>
    <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226; Metabolic Program (ThermoStem&#174;): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using
      brown adipose (fat) derived stem cells to generate brown adipose tissue (&#8220;BAT&#8221;). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased
      amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.</div>
    <div style="text-align: justify; margin-top: 12pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Forward-Looking Statements</div>
    <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended,
      and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements
      are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including,
      without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on
      such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.</div>
    <div style="text-align: justify; margin-top: 12pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CONTACT:</div>
    <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Email: ir@biorestorative.com</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>brtx-20240206.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<xs:schema targetNamespace="http://biorestorative.com/20240206" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:brtx="http://biorestorative.com/20240206" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20240206_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20240206_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://biorestorative.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>brtx-20240206_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>brtx-20240206_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://biorestorative.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="brtx-20240206.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219878472432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  06,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BioRestorative Therapies, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001505497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">30-1341024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">40 Marcus Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Melville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">760-8100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">BRTX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BRTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MWY4A-KTS:Z9O@F5+CW]:K9^5TM\H_=6L "Q[R=+<#+R5M<65[YMX!9DP9ZJ
M')\LE,Z$Q:9>^J;0())R4);Z81!T_4S(W!OVRWL3/>RKM4UE#A/-S#K+A'Z]
MAE1M!A[WWFX\R>7*NAO^L%^()4S!_E9,-+;\2B61&>1&JIQI6 R\$;^Z#B,W
MH.SQ6<+&[%TS-Y6Y4E]=XSX9>($C@A1BZR0$_CS#&-+4*2''/SM1KWJG&[A_
M_:9^5TX>)S,7!L8J_2(3NQIX%QY+8"'6J7U2FU]A-Z%SIQ>KU)1_V6;;-XH\
M%J^-5=EN,!)D,M_^BI==(/8&=/B! >%N0%AR;U]44MX(*X9]K39,N]ZHYB[*
MJ9:C$4[F;E6F5N-3B>/L\$;%:PRR92)/V&UNI7UE]_EVM3%J?=_B2UQ7/]X)
M7F\%PP."=S _8T'WA(5!&/UWN(]L%6!8 8:E7N> WE@]@V9_C>;&:ES"OYN(
MM@I1LX++ZRM3B!@&'B:N ?T,WO#=#[P;_$SP=2J^#J5>!W#V6D 3'#W\XO0]
M 1%5$!&I,D*"I*2X2\6RB8(>OQ"I 8+CO.(X/RX8$]!2N81*&*9E8UQHI3*-
MRCQJ2Z1NQ=8E%7?)?2=38(_K; ZZB8K6" )^VNEU@P[!TZMX>L?P/,%2NM3&
MH#V*K#%2M,ZU5$^ /J&%\S<V6X$6A01S@M]Q?$: 7E2@%\> CG%=M4A1-8$7
M]AY>FU!II0#C=QZ<1Y<] NNRPKH\!@LGJ711SE[E)VQJ,=V8TFRLULB+V"II
M#"HM_OB9(.1!;:[!,8PS\<+N$XR?7,BX!"4RL$6R$YSR3L3I;X+OV3\_AG"4
M)&B-F#.["_8!^[&/>6/H6B2C@#T(C;6+W6C,2 JS+@*<]/#O,,>NA:L\4YOF
M&D7+/4#Z+-.49*L+ *<M_%NV*@4G6CW+/&Z.(:WY^ >%5I<%3OOZMV@392Q^
MPG_*XN!WT:+(>2^BOEY>EPI..WRYA"/<21Y&H06Z'4Z!U'6!TZ;^0<48D\E*
MY51A:!'!HG!ZP8. (JHK Z<M?28M%BFU8#S\<?X3FT*\UABM1JR6XO T^YU"
MJFL IZU[ID4B\R6;OF9SE3:2T )M)+7M<]J:WZ+!;E_BE<B7<+!NM@@]CJ8W
MHT_4%K7V^? HG[_-0"]=E'Y!!;O"Q,X*D3>N6XM@VX8LK T^I-WX"\;*0NY8
MLG6^*S^F$8D6:D7:V]'3[CM5J8RE=8%Z0*O44C0F5(M**T]MX"%MMA,-IS&&
M!]"KMUMYW$WCH>/C8M'L!2UZK62U?X>TVWY'=F_,&LE: ?_G=M_?.TBZ0SG6
M<<QGPU)8H%!PUD-'UMMS[K9A55&>+>?*XDFUO%R!0#;7 9\OE+)O#7=<K?[;
M,/P74$L#!!0    ( #>!2%B?H!OPL0(  .(,   -    >&PO<W1Y;&5S+GAM
M;-U7;6O;,!#^*T(_8&YB:N*1&+9 8;"-0O-A7Y58=@1Z\62Y<_KKI[-L)VEU
M9=V'L<VAR=T]NKM'=R>9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND
M,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&
M@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-
M!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+
MY2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3), Z)Q17B@%JXUF X?)8Q1\
MV .7\@%:^*VZBMU7)/3B4PEM(+#52?2$1C&$"0K$OXP68E^$O?VML*01C\9]
M[/QN]*!_[XSC]Y97HA_TOIKS8]$7>'36-/+T08I:*Q[V_LL)BS6;_,C16/'D
ML\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y
M+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^
M7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!
M)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z
M!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C
M$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7
M,6[8"<:1/,<0F,7XC&894IT,/O'^8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T
M> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( #>!2%B7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ -X%(6!PX9>H_ 0
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M 5!+ 0(4 Q0    ( #>!2%@'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ -X%(6)4'347N    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ -X%(6)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    "  W@4A8NN^L&CL$  !Y$   &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ -X%(6)^@&_"Q @  X@P   T              ( !?@P  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    "  W@4A8EXJ[',     3 @  "P
M@ %:#P  7W)E;',O+G)E;'-02P$"% ,4    "  W@4A8'#AEZC\!   \ @
M#P              @ %#$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M-X%(6"0>FZ*M    ^ $  !H              ( !KQ$  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ -X%(6&60>9(9 0  SP,  !,
M             ( !E!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  WA,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="brt8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="brt8k.htm">brt8k.htm</File>
    <File>brtx-20240206.xsd</File>
    <File>brtx-20240206_lab.xml</File>
    <File>brtx-20240206_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "brt8k.htm": {
   "nsprefix": "brtx",
   "nsuri": "http://biorestorative.com/20240206",
   "dts": {
    "inline": {
     "local": [
      "brt8k.htm"
     ]
    },
    "schema": {
     "local": [
      "brtx-20240206.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "brtx-20240206_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "brtx-20240206_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://biorestorative.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20240206to20240206",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brt8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240206to20240206",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brt8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001021771-24-000033-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001021771-24-000033-xbrl.zip
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M>M-AZ'36A+:3'+8BZUPPK;.#\WO@03"+VL9+)@E-2!(S!U&-2_R0^&E"G"F
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M.)WEQ JJT%1,\N1N4=+-,#R((YP+;'(7\<^X!IPLC=_Y-A5S:<)KYENL8W0
M\S@*=S%CG%7K U!\I2FH!E6TC/Q0BW.=%#6(F?4+LQS_35L65H_.LOCO("OX
MCCI$5=6VHIL]609_D6U3W@GS"!@>1V:>EWD=C#M74@\X:V4 5ZDQK[J!F_-!
M:?U%Q?,MPYH8H@F_#U0!9YZ(,!,:;..MD2MUE9.>+NG*X5$NB)WX.1_@ _]C
M'C(B9VA$^09U;RBL60)1=RXN%*KP(+,9<\7VS\-:)Y( -)DV>=%?,(6D+Z%
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M?N/D>)N$)X.'-'T\'H^?GIY&3],1H:NQ]_KU9/SGI\N[X &O_6$8)ZD?!WB
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MD@GJ@-SN3MWGV^"!;08&'HBQ2913N"QQ<!HO&[H^E0/>5:=S+64F(DB$>O!
MC'7#2+T%AL_L9;5Z=M>=BG<XEM;BDGWB;_XMFL+\3;FS_P%02P,$%     @
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ML+,,\X7PZ1?.'HKE*<M6B-IO?KW(RMV0 PE/_O:%M;H?<B329H#<%/M3>+C
M5'#.UE3]JF<^"N?%J'5R8.!)WZ:8!M$=*;3<D#M>MRPE,2F$5[^A G."S,LR
M-T ?X2T >"HWEM%T=+>,U_I"[G--.9:VQ#3&Y3\HY']V^/5\7KM/;@:JA?(!
MX>G>NJP&_7UYM \@][D,_A=YOL:\M1N<<+LG+'#PSF@J<3]_6+)IEQS:2SL)
M:TMX*3;(OZ!O(_)%_F7[X_]02P$"% ,4    "  W@4A83Q]55ZH7  #A?P
M"0              @ $     8G)T.&LN:'1M4$L! A0#%     @ -X%(6.;7
MVO], P  3 \  !$              ( !T1<  &)R='@M,C R-# R,#8N>'-D
M4$L! A0#%     @ -X%(6(T$STR "   =5@  !4              ( !3!L
M &)R='@M,C R-# R,#9?;&%B+GAM;%!+ 0(4 Q0    ( #>!2%@AC)M+X@4
M /X^   5              "  ?\C  !B<G1X+3(P,C0P,C V7W!R92YX;6Q0
52P4&      0 ! #\    %"H

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>brt8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="brtx-20240206.xsd" xlink:type="simple"/>
    <context id="c20240206to20240206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20240206to20240206"
      id="Fact_78f3c570716a4a22b1ba1a04fbf8f808">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20240206to20240206"
      id="Fact_64abddf646f24eae90547bf0ef75095e">0001505497</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20240206to20240206"
      id="Fact_1f57f7206e734448aa8e50810b708215">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20240206to20240206"
      id="Fact_a4f29460a15e45e5bf188614a1aca9d0">2024-02-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20240206to20240206"
      id="Fact_458235bfc8b642588ab640ef2cd241f8">BioRestorative Therapies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20240206to20240206"
      id="Fact_b2cfda17f0f64ab584c03fdfde2ccc50">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20240206to20240206"
      id="Fact_b6afabd87de0467b9eb57b06f09b9eb8">001-37603</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20240206to20240206"
      id="Fact_a170d5152f2349ed95f7ef9b2c655bfc">30-1341024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20240206to20240206"
      id="Fact_a8b8f1f2d3a84899a626646b12361390">40 Marcus Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20240206to20240206"
      id="Fact_55c7ab22e710472c9ee246169f7c5e27">Melville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20240206to20240206"
      id="Fact_3fc4312b45b049f7b96091f26caa3f2e">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20240206to20240206"
      id="Fact_55a1e10a132e48709d99f5b66662646c">11747</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20240206to20240206"
      id="Fact_444fb7fa872f45508900b3c5a3e2629b">631</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20240206to20240206"
      id="Fact_3d21d989d12a4fa5819e6384ecfc7e41">760-8100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20240206to20240206"
      id="Fact_f4f88e3acb8249a697e015f15babf183">BRTX</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20240206to20240206"
      id="Fact_c7a42475c0cb4e90b411dd27e549447a">BRTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20240206to20240206"
      id="Fact_ce0e7922fcdb4fffb7c34510457aef41">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="c20240206to20240206"
      id="Fact_ba3ebbc81a9b44499af20cca3f5090df">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20240206to20240206"
      id="Fact_e77c6ff7804f4590aa4741e8de7df057">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20240206to20240206"
      id="Fact_85922a44fd364043b03c836711939c8f">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20240206to20240206"
      id="Fact_a68e741c5a4243d3a55dc1e3aa3b1013">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20240206to20240206"
      id="Fact_777d37ca4b0b4e3aaada88abb46bd273">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
